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Abstract
There is increasing interest in in-vitro methodology for testing chemical toxicity, 
one of the drivers for this is European legislation; specifically Directive 76/768 
EEC, which prohibits animal testing in the cosmetic industry. In skin 
toxicological testing, an alternative methodology to in-vivo irritancy experiments 
already available uses a synthetic skin model and involves measurement of cell 
viability and release of cytokine interleukin (IL) -1a. There is currently no fully 
validated in-vitro test for sensitization, although there are a number that are in 
development. Some of these include the human cell line activation test (h- 
CLAT) (Sakaguchi et al., 2010), the direct peptide reactivity assay (DPRA) 
(Gerberick et al., 2009) and the myeloid U937 skin sensitization test (MUSST) 
(Ade et a/., 2006). This study utilises ex-vivo human skin as an initial platform 
for method development. Areas of analysis have included the lipidomic and 
proteomic responses of ex-vivo human skin to sensitizers and irritants.
Matrix assisted laser desorption ionisation- ion mobility separation- mass 
spectrometry (MALDI-IMS-MS) was used to identify peptides and lipids in-situ. 
Ion mobility separation allowed for discrimination between isobaric species due 
to the selection of specific precursor ions and cleaner MS/MS spectra. Many of 
the peptides identified belonged to serum albumin, keratin and collagen protein 
families, which are known to be abundant within human skin. Lipids identified 
included: sphingomyelin, glycerophospholipids, ceramide species and
di/triglycerides.
In skin studies performed in other research groups, sphingomyelin and 
ceramide species were found to change expression in response to initiation of 
inflammation, thus making them of biological significance when investigating 
lipidomic responses to chemical sensitizers and irritants. Tryptic peptide 
MALDI-MS images have shown differences in human skin, as a result of 
chemical exposure. MALDI-MS images at 150pm and 30pm resolution have 
provided information on the localisation of detected species. Changes in 
expression of species in treated and untreated samples, as well as between 
different layers of human skin have also been visualised via multivariate 
statistical analyses. These analyses of ex-vivo human skin have demonstrated 
that MALDI-IMS-MS is a technique which can be used to detect changes in 
protein/peptide and lipid profiles in response to sensitisers and irritants. The 
technique also allows for the localisation of species detected within the different 
layers of human skin.
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Chapter 1: Introduction
1.1 European Legislation
In 2003, the European Union (EU) introduced new legislation in the form of the 
seventh amendment to the EU directive 76/768/EEC. This is a directive 
concerning a ban on the testing of cosmetics ingredients and products on 
animals. This legislation has been gradually phased in since 2003. In 2004, the 
testing of whole cosmetic products on animals was prohibited within the EU. In 
2009, the prohibition of the testing of cosmetic formulations and their 
ingredients on animals was introduced. A ban on the sale of cosmetic products 
or ingredients tested on animals for the remaining test areas (e.g. toxicological 
data gathering) is to be put into place in 2013. It is hoped that alternatives to the 
animal tests will be available by 2013, however if this is not the case, the ban 
could be delayed by further legislation.
The testing of individual cosmetic ingredients for their irritancy and sensitising 
potential is one such test for which alternatives must be found. A validated in- 
vitro test for skin irritants already exists (as explained later in section 1.2.3.2). 
However this is not the case for skin sensitisers. A skin irritant produces an 
immediate inflammatory immune response but does not engage the adaptive 
immune system (Nosbaum et al., 2009). A skin sensitizer however, acts as an 
allergen and causes the endogenous cells to mount an adaptive immune 
response (Kimber et al., 2008), leading to future hypersensitivity. This process 
is further explained in section 1.2, to follow.
2
1.2 Skin Sensitization
According to Kimber et al., (2008) skin sensitization is something that occurs 
after topical exposure to a contact allergen resulting in the induction of a 
cutaneous immune response of an appropriate magnitude. Any subsequent 
contact with the allergen results in the exhibition of a dermal inflammatory 
response. This is due to the primary and secondary adaptive immune 
responses. The initial cutaneous immune response that comes with first 
contact is known as the primary immune response. The primary immune 
response rarely provokes symptomatic expression, however memory cells 
remain and are largely responsible for the secondary and subsequent immune 
responses. Here the antigen is recognised by memory CD4 T lymphocytes and 
the immune response occurs more rapidly and on a larger scale, thus inducing 
visible symptoms including: redness, heat and swelling in the affected area.
It is widely recognised that Langerhans cells (LCs) are involved in the process 
of sensitization and subsequent inflammation. Figure 1.1 illustrates the role of 
Langerhans cells after exposure to a sensitizing agent. The Langerhans cells 
recognise the foreign molecule/body, internalise it and process it before 
migrating into the lymph nodes and initiating the primary immune response by 
presenting the antigen to T lymphocytes. The detailed process, however, is not 
fully understood. The increase in IL-1 p expression by LCs has been recognised 
since 1992 when Enk et al., discovered an increased expression of IL-1 (3 mRNA 
in LCs. However, IL-1 a is one of the initial cytokines that is expressed by LC 
when an irritant or sensitizer comes into contact with skin (Weiss et al., 2004).
3
Danger signals (TNF- a, iL m , 
CD40L, LPS, etc.) 4. Antigen PresentationAntigen
o
3. LC Migration
2. LC
Activation Lymph node
IL1-p
CD54 (ICAM-1)
* " “ o  y  .3 I Antigen
CCR7
Class II 
MHC
CD80
CD86
Figure 1.1: A diagram illustrating the role of Langerhans cells (LCs) in the
process of skin sensitization and upon subsequent exposure to a particular 
chemical allergen. The allergen penetrates the skin surface and the LC are 
activated by pro inflammatory cytokines before migration into the lymph nodes. 
Abbreviations include tumour necrosis factor (TNF), intercellular adhesion 
molecule (ICAM), major histocompatibility complex (MHC), cluster of 
differentiation (CD), lipopolysaccharide (LPS) (Ryan et al., 2007)
This makes it less useful as a means to distinguish between the two chemical 
types. CD 54, 80, and 86, as pictured in Figure 1.1, become up regulated as a 
result of LC maturation into DCs (Basketter et al., 2007). An et al., (2009) found 
the up regulation of these CDs to be particularly significant prior to the exposure 
of cells to sensitising agents such as DNCB. According to Ryan et.al., (2007), 
chemokines such as CCL21 and CCL19 play a role in the guidance of migrating 
LCs into the peripheral lymph nodes where an adaptive immune response is 
initiated. It may be that chemokines such as these are specifically expressed 
as a result of sensitization and could help to identify this response separately
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from irritation. Another cytokine that is reported to be involved in the process of 
skin sensitization, and also other allergic responses including asthma (Wild et 
al., 2000) is interleukin 18 (IL-18). When exposed to an allergenic stimulus the 
inactive IL-18 is cleaved by caspase-1 to become active. Activated IL-18 plays 
a role in the stimulation of migration of LCs and DCs (Cumberbatch et al., 
2001). IL-18, like the majority of inflammatory cytokines and chemokines, are 
found in the epidermis (Cumberbatch et al., 2001), making this a particularly 
important area for investigation of skin in this research project.
1.2.1 Sensitisation Testing
1.2.1.1 In-vivo Testing
The established methodology for testing sensitizing chemicals is the murine 
local lymph node assay (LLNA). This method involves the exposure of the 
animal to the test chemical in question. Subsequent to this exposure, the 
animals are sacrificed and the auricular lymph nodes are removed and 
disaggregated to produce a single cell suspension of lymph node cells 
(Basketter et al., 2002). Cells are counted and the level of lymph node cell 
proliferation should increase if a sensitisation response is initiated. The test 
gives a positive result if cell division is increased more than 3-fold compared to 
the normal level of cell division (Basketter et al., 2000). This procedure is 
strictly monitored to minimise the number of animals sacrificed. Despite this 
fact, this in-vivo test raises many ethical issues and as a result legislation such 
as the EU directive 76/768/EEC was brought in, in order to encourage and force 
cosmetic and chemical companies alike to strive to find an in-vitro test. An in- 
vitro test that mimics the human response to sensitizing chemicals as closely as
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possible would be most suitable as even with the current in-vivo experiments 
not all toxicological data from animals can be successfully extrapolated to 
human immunological responses.
1.2.1.2 In-vitro Testing
A validated in-vitro test has been developed for the identification of irritant 
chemicals. This test involves the use of EpiDerm FT™ (MatTek Corp., Ashland, 
MA, USA) as a synthetic platform to which a chemical is applied. This is a 
synthetic model of the stratum corneum, epidermal and dermal layers of skin 
(as labelled in Figure 1.2), reconstructed from human cells.
Stratum Corneum
Epidermis
DermisI V^iable fibroblasts
Figure 1.2: Haematoxylin and Eosin stained paraffin section of EpiDerm FT™, 
revealing the epidermis containing basal, spinous, granular keratinocytes and 
stratum corneum, with the dermis, containing viable fibroblasts (x400 
magnification). As adapted from MatTek Corporation, Ashland, MA, USA 
(http://www.mattek.com/paqes/products/epidermft).
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Subsequent to the application of the test chemical, the 3-(4,5-Dimethylthiazol-2- 
yl)-2,5-diphenyltetrazolium bromide (MTT) test and measurement of IL-1 [3 within 
the EpiDerm FT™ is then implemented (Kidd et al., 2007). As explained in 
section 1.2, this is something that is only useful in the identification of skin 
irritants as further evidence would be required to distinguish the sensitizing 
chemicals from the irritants. Although no commercially validated alternative has 
yet been developed, some potential in-vitro tests for sensitization have been 
investigated. There is a common theme as to which known sensitizers are used 
in the development of these in-vitro tests. One of these chemical sensitisers is
2,4-dinitrochlorobenzene (DNCB), which despite its extreme potency as a 
sensitizing agent is still a good option for development purposes, due to the low 
likelihood of exposure outside of the laboratory. DNCB has been used in 
conjunction with mass spectrometry (MS) for the analysis of its skin sensitizing 
properties in the past (Aleksic et al., 2007 and 2008). This group found that 
MALDI-MS was a viable method for the detection of proteins modified as a 
result of DNCB exposure. Tryptic digestion of cytokeratin 14, cofilin and human 
serum albumin (HSA) was performed and peptides were detected. Subsequent 
to DNCB exposure, new signals were detected and identified through the 
attributing mass shifts to hapten adducts. This provides a valuable insight into 
the behaviour of DNCB as a sensitizing agent; however the information is 
limited by the protein scale at which the experiment is performed.
By only studying selected proteins, however, the full picture of events cannot be 
realised. These experiments provide limited contribution to the development of 
an in-vitro test aimed at identifying new potential skin sensitizers as they look at 
the way in which a specific agent affects the skin and it is well recognised that 
sensitizers have varying modes of action. Therefore, if each different
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sensitizing agent was to be analysed separately prior to the development of a 
test the timescale would be far too prolonged and expensive, considering the 
imminent demand. Instead it may be suggested that a test which can identify all 
classes of sensitisers, or a number of tests which combine to that effect, needs 
to be developed prior to the full investigation and understanding of mechanisms.
One of the most common routes to developing an in-vitro test for sensitizers 
that has been taken is the use of cell based assays. The use of the human 
monocytic cell line, THP-1 has been documented in several papers as a method 
for sensitization tests. Yoshida et al., (2003) found that THP-1 cells behaved 
similarly to LCs when treated with the skin sensitizer, DNCB. This study found 
that unstipulated THP-1 cells, in which cytokine expression was not induced, 
showed increased expression of CD54 and CD86 when exposed to DNCB. 
This is a response that is also seen in LCs in vivo, and these cells are known to 
play a significant role in the skin sensitization process. Another interesting 
finding was that this response was not seen when the cells were treated with an 
irritant sodium lauryl sulphate (SLS), showing the potential for this test to 
discriminate between irritants and sensitizers on the basis of expression level of 
CD54 and CD86.
The investigation described above has been followed by a number of other 
research studies into the potential use of THP-1 cell line as a platform for an in- 
vitro test for skin sensitization. Ashikaga et al., (2006) from the same research 
group performed further optimisation of the use of THP-1 cell lines and 
proposed to call their in-vitro test the human Cell Line Activation Test (h-CLAT). 
In this method they screened the cell lines for CD86 and CD54 expression as 
markers of sensitization. One concern with this method is that not all sensitizing
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chemicals are able to initiate a response in expression of these two markers, 
whilst still at sub-toxic levels (Ashikaga et al., 2002).
1.3 Human Skin
In this project, ex-vivo human skin has been used as a model for the 
development of a MALDI-MS method for the identification of chemicals which 
induce an irritant or sensitizer response. It was hoped that once a method was 
developed it might then be possible to transfer the protocol for human skin to 
one suitable for synthetic skin models, similar to EpiDerm FT™ (MatTek Corp., 
Ashland, MA, USA). However, the model system would require incorporation of 
viable LC. It was more feasible to use ex-vivo human skin for all initial
pore
investigation as this is much more cost effective than the synthetic models, 
which are expensive and this would then restrict the range of testing variables 
that could be explored.
5weat gland
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Figure 1.3: A diagrammatic representation of the structure of human skin, as
taken from MacNeil (2007).
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However for a universal testing system for sensitisers, a synthetic model will 
allow for worldwide implementation and greater consistency. A recent 
development toward this has been discussed by Canton et al., (2010). In this 
study 3D reconstructed models containing transfected human fibroblasts and 
keratinocytes were tested for their ability to differentiate between an 
inflammatory response to an irritant and a more cytotoxic response, usually 
attributable to exposure to stronger chemicals or those of higher concentration.
Human skin consists of 3 main layers; the epidermis, the dermis and the 
subcutaneous tissue, as can be seen in Figure 1.3. The stratum corneum is the 
upper-most layer that is exposed to the external environment and this largely 
consists of dead cells such as keratinocytes. The lowest layer of skin/tissue 
that is present in the ex-vivo samples used in this research is the subcutaneous 
tissue, which is largely composed of adipose tissue, also indicated in Figure 1.3. 
The most important layers when investigating skin irritation and sensitization are 
the epidermis and dermis. It is in these two layers that the foreign molecules are 
internalised by LCs, processed and then externalised by the presentation of an 
antigen in association with MHC molecules on the outer membrane of the LC 
(as illustrated in figure 1.1) (Ryan et al., 2007). Many of the proteins that are 
routinely investigated when testing the skin’s response to chemicals have 
normal physiological roles within the skin. Interleukin 1 is known to stimulate 
the production of collagenase (Postlethwaite et al., 1983) and it has been 
reported that in murine skin this also results in the increase in collagen IV 
(Matsushima et al., 1985). Proteins that are normally found in human skin are 
known to be altered as a result of endogenous and exogenous factors (e.g.,
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autoimmune diseases, stress and aging), collagen included (Kahan et al., 
2009).
It is not just proteins that have key roles in the homeostasis of human skin, 
lipids also have an integral part to play. A large number of sphingolipids and 
their metabolites are distributed throughout the stratum corneum and epidermis. 
Due to their co-existence and interaction with other biological molecules, such 
as proteins and peptides (Doering et al., 1999), lipids are often involved in 
disease pathogenesis (Fujiwaki et al., 2002). It has been established that 
sphingosine (Sph), sphingosine-1-phosphate (S1P), ceramide (Cer) and 
ceramide-1-phosphate (C1P) all have roles in apoptosis, amongst other cell 
signalling pathways (Bartke eta!., 2009).
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1.4 The Technique: Mass spectrometry (MS)
Mass spectrometry is primarily used as a technique for the molecular 
investigation of compounds of known and unknown identity. Mass spectrometry 
can be both qualitative and quantitative. There are many different types of 
mass spectrometry, though the research reported in later chapters refers to the 
application of matrix assisted laser absorption ionisation (MALDI) -  MS and this 
will be the focus of this review.
1.4.1 Ionisation Sources
A number of different ionisation sources are employed in mass spectrometry; 
these include; electron ionisation, atmospheric pressure chemical ionisation 
(APCI), electrospray, and matrix assisted laser desorption ionisation (MALDI). 
The ionisation mechanisms of each of these technologies make them more or 
less suitable for the analysis of different sample types. Electrospray, APCI and 
MALDI are considered to be “soft” ionisation techniques, this means that they 
are more useful in analysis of molecules of greater relative molecular mass 
(RMM). Harsher ionisation sources, such as electron ionisation are less suited 
for such purposes as the processes occurring during ionisation can sometimes 
cause extensive fragmentation of the molecules (Morris et al., 1981). For the 
multi-molecular purposes of investigation in this study, two of the more suitable 
ion sources would be ESI and MALDI, due to their versatility in analyses.
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1.4.1.1 Electrospray Ionisation (ESI)
Electrospray ionisation (ESI) is a common form of ionisation in mass 
spectrometry and is most frequently used in the analysis of peptides and 
proteins. The main theory regarding the mechanism of ESI is that of coulombic 
fission. The basic principles of this are seen in Figure 1.4. A charged, liquid, 
analyte droplet is injected in to the ionisation source, via a charged capillary 
needle. The droplet then undergoes solvent evaporation whilst travelling toward 
the counter-electrode (as labelled in Figure 1.4). As this occurs, the multiply 
charged analyte molecules are forced together, until the repulsive forces 
overwhelm the surface tension of the droplet (known as the “Rayleigh limit”) and 
coulombic fission occurs (Kebarle et al., 2009). Eventually, gaseous phase 
analyte ions are formed and taken into the mass analyser.
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Figure 1.4: Schematic diagram displaying the basic mechanisms of
electrospray ionisation, from liquid entry via the capillary tip to the exit of 
gaseous phase ions into the mass analyser, as modified from the University of 
Bristol, Mass Spectrometry Resource (ESI);
http://www.chm.bris.ac.uk/ms/theorv/esi-ionisation.html.
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There are two main theories to the processes that lead up to the event of 
coulombic fission. These are that of ion evaporation and charged residue (also 
known as dried droplet) (Crotti et al., 2011). As discussed by Kebarle (2000) 
and Cole (2000), the charged residue mechanism involves a series of scissions 
of the droplet, with each successive divide, producing droplets of smaller 
dimensions, until such a point where single molecules are produced. The ion 
evaporation mechanism involves the desorption of single analyte molecules 
from the droplet, each time the Rayleigh limit is reached (Thomson and Iribarne, 
1979).
1.4.1.4 Matrix Assisted Laser Desorption ionisation (MALDI) Mass 
Spectrometry
Brief History
The principle of MALDI-MS was described by Karas etal., (1985) and applied in 
1988 by Karas and HillenKamp (Karas et al., 1990). However, Tanaka of 
Shimadzu Corporation was also working on this technology at the same time 
(Tanaka et al., 1988) and as a result there is still much dispute over who 
actually initially developed the technique. Even at this early stage in the 1980s 
it was found that MALDI-MS was capable of detecting molecules of molecular 
mass up to 300,000 Daltons. Since then the technique has developed 
extensively. A number of lasers have been used, which operate at varying 
wavelengths and emit differing levels of energy (Hoffmann et al., 2007), as 
detailed in Table 1. Initially MALDI MS was used for the analysis of liquids 
spotted onto a target plate and the generation of single spectra. Due to its 
limited requirement for sample preparation in comparison to previous successful
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forms of mass spectrometry, MALDI-MS is now a popular tool in analytical 
science.
Laser Wavelength Energy (eV) Pulse Width
Nitrogen (N2) 337 nm 3.68 <1 ns to a few ns
Nd:YAG p3 355 nm 3.49 5 ns
Nd:YAG p4 266 nm 4.66 5 ns
Er:YAG 2.94 pm 0.42 85 ns
C 02 10.6 pm 0.12 100 ns + 1 ps tail
Table 1.1: Specifications of lasers commonly used in MALDI-MS. As taken 
from page 36 of Hoffman et al., (2007).
MALDI MS imaging (MSI) of biological tissue was first described in a study by 
Caprioli et al., (1997). In this study, imaging was only performed with an 
acquisition range of 50,000 Daltons and was used to examine small areas of 
mammalian tissue; the pancreas and pituitary, excised from Sprague-Dawley 
rats. There are many examples of MALDI MSI analysis of rat tissue some of 
these have been used to show localisation of drugs in full body sections (Trim et 
al., 2008). MALDI imaging has also been used to show distribution of 
xenobiotics in porcine skin as in studies by Bunch et al., (2004) and Prideaux et 
al., (2007). MALDI MSI has not only been used in the analysis of animal tissue, 
there are also examples of images that have been produced in the analysis of 
pesticides in plant tissue (Anderson et al., 2009). MALDI MS has also been 
used in analyses of inorganic substances, e.g. in the characterisation and 
general analysis of polymeric materials (Jagtap et al., 2005). The examples of 
applications of MALDI-MSI mentioned above show the versatility of the 
technique, this is still expanding as different research facilities are continuously 
making new discoveries through modifications to aspects of the technology.
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Fundamental Principles and Ion Formation
MALDI-MS is a soft ionisation technique, which means that it does not have the 
fragmentation potential of other forms of MS such as electron ionisation MS 
(Jagtap et al., 2005). This allows analyses to be performed in such a way that 
the molecules detected remain mostly intact. In MALDI analysis a matrix 
solution is deposited onto the sample of interest, this is essential for both the 
protection of analytes against the laser and for the whole ionisation process. 
The laser heats and excites matrix molecules causing their sublimation and 
ablation into the gas phase in a plume, which also contains analyte molecules 
from the sample surface (as depicted in Figure 1.5). Some ionisation occurs 
and gas phase ions are then accelerated toward the mass analyser.
Figure 1.5: A schematic diagram of the process of matrix assisted laser
LaserBeam
AnalyteIon
r  A  To Mass Analyzer
MatrixIon
Analyte/Matrix
Mixture
ionisation desorption ionisation. Diagram taken from:
http://www.siliflow.com/proteoMaldilmaging.php.
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In the past, there has been much speculation surrounding the mechanism of 
ionisation in MALDI. It has been suggested that the different types of ions that 
are formed during MALDI are as a result of different mechanisms. The 
mechanism for the production of analyte ions can be split into two stages 
primary ion formation and secondary ion formation. Some of the primary 
mechanisms previously suggested include: multiphoton ionisation, excited state 
proton transfer, thermal ionisation and desorption of ions that are formed prior 
to analyses. Secondary ion formation reactions that have been proposed 
include: gas phase proton transfer, cluster ionisation, and gas-phase 
cationisation (Zenobi et al., 1995). The most popular theory is that of proton 
transfer between the matrix clusters and analyte molecules, as investigated by 
Land and Kinsel (2001) and demonstrated in the following equation showing 
theoretical proton transfer in positive mode ionisation (Knochenmuss et al.,
2003).
[M+H]+ + A —> M + [A+H]+
Sample Preparation
Sample preparation is an integral part of MALDI MS analysis. There are two 
main factors to consider when developing sample preparation methods for 
imaging of biological tissue, some of these include matrix (its composition and 
application) and tissue preparation.
Matrix Composition and Application
There are a variety of different matrices that can be used in MALDI imaging 
analysis depending on the type of compound under investigation. Some 
matrices are effective in the positive ionisation mode of a mass spectrometer.
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a-Cyano-4-hydroxycinnamic acid (a-CHCA) is one of these matrices and is 
particularly efficient when attempting to detect small molecules such as drugs 
and lipids (Trim et al., 2008), also for the analysis of peptides after the tryptic 
digestion of tissue (Djidja e ta i, 2009).
2,5-dihydroxybenzoic acid (DHB) has also been used in the analysis of small 
molecules, proteins and glycoproteins. Garaguso e ta i,  (2008) investigated the 
use of an improved application of a DHB matrix for the MALDI-MS analysis of 
peptides. This study involved a method of application known as ‘matrix layer’ 
(ML) for comparison to the more commonly used ‘dried droplet’ method. The 
ML method involved the application of the matrix solution, then that of an 
acidified analyte solution and finally recrystallization was performed through the 
application of a third layer, an 80:20 ethanol, 0.1% trifluoroacetic acid (TFA) in 
water solution. This procedure is rather more complicated than that of the dried 
droplet application method, however results show that better crystallisation and 
homogeneity is achieved with the ML method (Garaguso et a i, 2008).
One of the more popular matrices for the analysis of intact proteins is sinapinic 
acid (SA). More recently this has been used in conjunction with aniline. Franck 
et a i, (2009) reported the use of a matrix solution of 20mg/mL SA with an 
equimolar concentration of aniline dissolved in acetonitrile (ACN): aqueous TFA 
0.1% (60:40, v/v). The matrix was applied using an automated CHIP 1000™ 
(Shimadzu Biotech, Manchester, UK) matrix printer. When applied to the 
tissue, the matrix solution containing aniline was found to provide increased 
homogeneity in crystallization compared to SA alone as well as improving 
sensitivity, resolution and signal strength. This is advantageous as in the past 
automated matrix deposition methods have not allowed for the use of higher 
concentrations of matrices such as those required for the analysis of intact
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proteins, due to problems such as the matrix coming out of solution and 
blocking essential parts of equipment. Therefore this may provide a more 
consistent application of matrix onto tissue than the less reproducible manual 
spraying techniques.
There are a variety of devices for the automatic deposition of matrix, some of 
these include; the Portrait® 630 Spotter (LABCYTE™, Dublin, Ireland), the 
SunCollect™ automated sprayer (KR Analytical, Sandbach, UK); the automated 
CHIP 1000™ (Shimadzu Biotech, Manchester, UK) inkjet printer; and the 
ImagePrep (Bruker Daltonics, Coventry, UK). The Portrait® 630 Spotter is an 
acoustic spotter and works by ejecting a spot of solvent/matrix from a reservoir 
in an upward direction onto a target above the reservoir. In order to coat an 
area of a sample, the target holder is automatically moved between each 
ejection, with a typical distance of approximately 200 pm between each spot 
(Aerni et al., 2006). Although this instrument does not have the disadvantage of 
capillaries or tubing becoming blocked, it is possible for higher concentrations of 
matrix to crystallize in the reservoir, altering the trajectory of liquid being ejected 
and necessitating the refilling of reagent within the reservoir at regular intervals. 
The Suncollect sprayer deposits a fine spray of matrix or reagent onto the 
surface of a sample at a flow rate of the operator’s choice (Djidja et al., 2010). 
This instrument is particularly useful for the deposition of a homogenous layer of 
matrix that is preferential for MALDI-MSI, whereas the spots deposited by other 
devices are clearly visible in processed MALDI-MSI, decreasing their suitability. 
One disadvantage of this technique is that the tubing, being of minimal internal 
diameter can get blocked by matrix crystals, therefore limiting the matrix 
concentration that can be applied. The CHIP 1000™ functions via ‘piezo­
electric print heads’, (Patel et al., 2009) that deposit matrix onto the sample
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surface, without physical contact. This method of application leaves a grid of 
matrix spots, similar to that of the Portrait 360, which again, is perhaps, more 
suitable for MALDI-MS profiling (Patel et al., 2009). Finally, the ImagePrep 
uses vibrations to vaporise the matrix and does so with the use of a piezo­
electric spray head. One advantage of this technique is the sensor that is also 
integrated into the instrument, which monitors how wet the sample becomes 
and how thick the matrix coating is (Walch et al., 2008), theoretically this should 
help reduce spreading of the analytes within a sample.
Tissue Preparation
The preparation of tissue prior to application of MALDI matrices for many 
different tissue types is vital to the quality of results obtained. Caprioli et al., 
(1997) and Stoeckli et al.,(2001) used pre-analysis washes for a variety of 
different biological tissue types. Tissue washing prior to analysis via MALDI-MS 
can be vital due to the requirement for the removal of salts and other impurities 
that may affect the process of ionisation. For proteomic studies this also can 
also include the benefit of protein fixing. Such tissue preparation mostly involves 
the washing of the sample prior to matrix deposition. There are a number of 
different methods and solvents that have been utilised for this.
The tissue washing procedures differ slightly depending on whether the tissue is 
left intact or digested for peptide analysis. In order to prepare tissue for intact 
protein analysis sources such as Lemaire et al., (2006) suggest the use of 
different organic chemical preparations for washing steps. In earlier studies, 
tissue sections have been washed with water (Chaurand et al., 1999). This 
method is now less frequently used for the washing of tissue as the water can 
cause disruption of the localisation of integral biological proteins and peptides. 
Recently, the most commonly used washing solvents are ethanol based. For
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example, in a study by Goodwin et al., (2008) a brief wash in 70% ethanol was 
employed, followed by a further wash in 90-100% ethanol. The first wash, with 
the aim of extracting impurities and the second, with that of tissue dehydration 
and fixation. This study also suggests the addition of chloroform in experiments 
where the removal of lipids is required. This is something which is of great use 
in peptide analysis of digested tissues. A report by Seeley et al., (2008) also 
discussed the possibility of combining methanol and chloroform for optimised 
washing and removal of lipids. This may be useful in preparation of tissues 
wherein lipids are in such great abundance e.g. brain, that chloroform alone is 
not sufficient without causing over-drying of tissue.
In one study by Chaurand et al., (2004) it was revealed that conventional 
histology can be combined with MALDI-MSI. The histological protocol 
consisted of ethanol based washes and the application of dyes, including: 
Terry’s Polychrome (TP), Toluidine Blue (TB), Nuclear Fast Red (NFR), Cresyl 
Violet (CV) and Methylene Blue (MB). Here, the mass range analysed was 
between 3,000 to 70,000 Daltons so would have focussed mainly on the 
detection of intact proteins. It may however be possible to apply this method to 
trypsin digested tissue as the study on intact proteins was successful. It was 
discovered that some of the different dyes increased the signal intensity of 
specific proteins. This is illustrated in figure 1.6.
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Figure 1.6: A plot displaying the relative intensities of MALDI-MS profiles taken 
from human glioma tissue that has been prepared and fixed using differing 
staining protocols. Spectra are labelled as follows: Terry’s Polychrome (TP), 
Toluidine Blue (TB), Nuclear Fast Red (NFR), Cresyl Violet (CV) and Methylene 
Blue (MB). (Chaurand et a i, 2004).
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1.4.2 Mass Analysers
There are different types of mass analysers, the most common of which, for 
MALDI instruments include: Q-TOF, ion trap and time of flight (TOF). In this 
study the mass analysers used were Q-TOF and TOF.
1.4.2.1 Quadrupole Mass Analysers
Quadrupole (Q) mass analysers are commonplace in mass spectrometry. They 
are often present as triple quadrupoles (QQQ) or in combination with other 
mass analysers (e.g. Q-TOF). When used in different combinations, the 
quadrupole assumes different roles, for example, when used in single MS mode 
in conjunction with TOF, the quadrupole will act as an ion guide (Chernushevich 
et al., 2001). When used in conjunction with other quadrupoles (e.g. QQQ), the 
Q2 analyser can be used as a collision cell, in which to perform CID. Coupling 
a quadrupole mass analyser to an ion trap can be advantageous as they allow 
ions through in pulses, enabling the accumulation at selected m/z ranges over 
time, whereas quadrupoles generally operate in a continuous mode (March, 
1997).
The trajectory of ions within a quadrupole field can be described mathematically 
using the Mathieu equation (March, 1997). To briefly explain this: the 
quadrupole field works in such a way that the ions travelling outwards, towards 
the poles are repelled back into the centre with equal force. This results in the 
oscillating flight path depicted in Figure 1.7. Ions not following this path are lost 
before reaching the detector.
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Figure 1.7: Schematic diagram displaying the basics of ion flight through a 
quadrupole mass analyser, as modified from the University of Bristol, Mass 
Spectrometry Resource (QQQ); http://www.chm.bris.ac.uk/ms/theorv/quad- 
massspec.html.
1.4.2.2 Time of Flight (TOF) Mass Analysers
A TOF analyser can be operated in linear or reflectron mode. Here, ions are 
accelerated into a straight drift tube. Ions are separated according to the speed 
at which they travel through the drift tube, with low mass ions reaching the 
detector faster than high mass ions (Hoffman etai., 2007).
Figure 1.8 shows schematic diagrams of a TOF mass analyser in linear mode 
and in reflectron mode. When in linear mode (Figure 1.8A), the main issue with 
TOF separation of ions is the potential for ions of the same molecular mass to 
reach the detector at different times. This is due to a difference in kinetic 
energy that cannot be compensated for fully in the linear drift tube. The
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schematic in Figure 1.8B, shows a TOF mass analyser that is in reflectron 
mode. The charged field, sometimes known as the “mirror” in the reflectron 
design, is implemented to reduce the effect of kinetic energy difference in ions 
of the same molecular mass. The ions travel through the drift tube and upon 
reaching the “ion mirror”, those with greater energy penetrate furthest into the 
reflectron (Cotter et al., 2007). This compensates for the difference in speed at 
which the ions are travelling and results in their simultaneous arrival at the 
detector. Theoretically this should provide sharper spectral peaks and as such, 
improve mass accuracy.
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Figure 1.8: A schematic diagram of a linear TOF mass analyser (A) and of a 
Reflectron TOF (B), and the flight path of ions through the drift tubes. These 
representations were adapted from Cotter etai., (2007) and Lennon (1997).
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1.4.2.3 Quadrupole -  Time of Flight (Q-TOF) Mass Analysers
Quadrupole time of flight (Q-TOF) mass analysers can be coupled with different 
ion sources, including MALDI and ESI. When run in normal MS acquisition 
mode, the quadrupole generally functions as a transmission device, whilst the 
TOF mass analyser is used to record the spectra (Chernushevich et al., 2001). 
When using a Q-TOF instrument for MS/MS acquisition, the first quadrupole 
may be used for transmission, the second, for precursor ion selection, the third 
as a collision cell, and the TOF for the recording of the ions. In recent 
instrument designs, such as that of the Synapt G2 (Waters Corp., Manchester, 
UK), the first quadrupole used for transmission, is replaced with a hexapole, as 
seen in the diagram in Figure 1.9.
Q-TOF MALDI-MS has been used for a multitude of different experiments, 
including the analysis of peptides (Wattenburg et al., 2002), and sequencing of 
glycans (Yu et al., 2006), etc. In the case of Yu et al., (2006) a MALDI Q-TOF 
MS is compared to MALDI- TOF/TOF. In this study, the MALDI TOF/TOF and 
its high energy CID capabilities, was found to be more useful and suitable for de 
novo sequencing. The Q-TOF was also found to be of value due to its easily 
interpretable MS/MS spectra produced by lower energy CID. Q-TOF mass 
analysers have also been found to be capable of producing valuable 
quantitative data with a good degree of mass accuracy, when coupled to an ESI 
source (Petrovic et al., 2006).
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1.4.2.4 Mass Analysers Based on Trapping Ions
Quadrupole Ion trap (QIT) mass analysers were first introduced in a patent in 
1953 (March, 2000). The design of ion trap instruments differs between 
manufacturers, though the principle is the same throughout. An ion trap works 
in principle, as the name suggests by trapping ions; ions exit the source with 
differing kinetic energies, and enter the ion trap where they become trapped in 
an electric field. Here ions of all masses are immobilised and their kinetic 
energies equalled. Once all ions are in the centre of the trap, a radio frequency 
(RF) voltage is rapidly applied, re-energising ions. Next the charges of the 
entrance and exit caps are reversed with the exit becoming positively charged 
and the exit, negatively. Ions are ejected towards the detector by scanning the 
amplitude of the RF voltage. A modern variant on the traditional ion trap designs 
is the Orbitrap (Thermo Scientific, Hertfordshire, UK), invented by Alexander 
Makarov and commercially released in 2005 (Brodbelt, 2009). The Orbitrap, is 
fundamentally different to a QIT mass analyser as, instead of employing a 
dynamic, radio frequency to energise ions, it uses an electrostatic field with ions 
in orbit around a central electrode. The main similarity between the two 
technologies is that the ion motion possesses an ‘harmonic potential’ (Hu et a i, 
2005). This refers to the oscillation frequency of ions when moving toward the 
exit of the traps. The frequency of the oscillation is proportional to mass and can 
be measured and converted to an m/z value by fourier transformation.
Fourier transform- ion cyclotron resonance (FT-ICR) is another type of mass 
analyser that has evolved from a conventional ion trap. On entry to the ion trap 
the ions are cooled by liquid helium and nitrogen to reduce kinetic energy. The 
ion trap in this case is within a super conducting high field magnet (Gates, 
University of Bristol, http://www.chm.bris.ac.uk/ms/theorv/fticr-massspec.html).
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known as a Penning trap. The ions are trapped in a cyclic motion which is 
excited by the application of radio frequency (RF) field. The effect of the RF on 
the cyclotron motion is measured and passed through the FT to produce a 
frequency spectrum, and subsequently, a mass spectrum (Marshall et a i, 1998, 
Kostyukevich et a i, 2012). This type of MS allows for high mass accuracy and 
high mass resolving power, making it a powerful tool for identifying species of 
similar m/z and also for the generation of images with increased 
specificity/selectivity (Smith et a i, 2012).
1.4.3 Ion Mobility Mass Spectrometry
Ion mobility spectrometry (IMS) was and is still used as a “stand alone” 
technique. It is marketed by the manufacturers as an ‘alternative to HPLC’ 
(DeBono, 2002), and in many ways this is true. Like high performance liquid 
chromatography (HPLC), IMS is an efficient method of separating molecules 
according to more than just mass alone. This makes both of these technologies 
useful additions to mass spectrometry, which separates according to mass. 
One advantage that IMS has over HPLC is the reduced amount of sample 
preparation that is required prior to analysis; this particular benefit is what 
makes IMS so useful for the detection of chemical agents, explosives, etc. 
within airports (Eiceman 2002). IMS has also previously been used in particle 
sizing (Bohrer et a i, 2008), and is used today, in combination with LC, and/or 
MS, for the analyses of biomolecules, such as tryptic peptides (Bohrer et a i, 
2008).
IMS has been applied to provide answers to a number of complex biological 
problems. In the study of Smith et a i, (2007), ion mobility was utilised in
29
conjunction with an electrospray ionisation source for the determination of 
protein conformation and separation of conformers. Ion mobility has also been 
used in conjunction with a MALDI ionisation source, as in the case of Djidja et 
a i, (2009). Here, ion mobility aided in the acquisition of MS/MS of tryptic 
peptides within biological tissue. The separation of peptides, lipids and matrix 
ions according to their conformation allowed for the production of clean MS/MS 
spectra even when precursor ions could not be differentiated by m/z alone. 
MS/MS with less interference from multiple precursor ion fragmentation has a 
greater probability of being matched to databases such as UniProt through 
databases like MASCOT (Matrix Science) and sequences are also easier to 
interpret manually. Therefore ion mobility is a valuable tool for increasing the 
number of peptides that may be identified within complex samples, such as 
biological tissue.
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Figure 1.9: A schematic diagram of a Synapt HDMS system (Waters Corp., 
Manchester, UK), with an electrospray ionisation source. Diagram adapted from 
Yu et a i, (2010).
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Kanu et a i, (2008) describe four main types of IMS that are used with MS. 
These are; drift time ion mobility spectrometry (DTIMS); aspiration ion mobility 
spectrometry (AIMS); field-asymmetric waveform ion mobility (FAIMS); and 
travelling wave ion mobility spectrometry (TWIMS). The ion mobility system 
used in this thesis was the Synapt G2 MALDI-HDMS (Waters Corporation, 
Manchester, UK) (Figure 1.9), and the form of ion mobility utilised in this 
instrument, is known as “travelling wave” technology. In basic terms, this 
involves the continuous flow of energetic waves upon which ions are propelled 
through the cylindrical IMS cell at differing speeds (Shvartsburg et a i, 2008). A 
diagram displaying the fundamentals of the travelling wave can be seen in 
Figure 1.10.
R in g  r k * c in * d c
Figure 1.10: A schematic diagram, displaying the movement of ions through an 
Ion mobility cell on a travelling energetic wave (as adapted from Giles et a i,
2004).
The travelling wave is generated by the stacked electrode rings. The speed at 
which an ion drifts through the pulsing waves is determined by its mobility and
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can be represented by the following equation, where, vd refers to drift velocity, K 
to mobility and E to electric field intensity:
vd = K . E
McDaniel et a i, (1973) describe mobility as being dependent upon: ‘ion and 
neutral masses, the charge on the ion and the interaction cross-section 
between the ion and neutral gas’. Ions of higher mobility are able to traverse 
the wave readily, with reduced drift time (Figure 1.10) However, ions of low 
mobility are not able to travel through the gas so easily and “roll back” over the 
energetic waves, increasing their overall drift time within the IMS cell (Giles et 
ai, 2004). This allows ions of the same mass to be separated by cross 
sectional differences in their structure. Smith et a i, (2009) have also 
demonstrated that drift time may be deciphered in order to calculate the actual 
cross sectional area of molecules.
1.4.4 Imaging Mass Spectrometry
Mass spectrometry techniques have been developed to image molecules within 
samples. Some of these include: MALDI-MS (as used in this thesis), secondary 
ion mass spectrometry (SIMS), desorption electrospray ionisation (DESI), and 
laser ablation electrospray ionisation (LAESI).
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Technique
Achievable
Spatial
Resolution
Operating
Conditions
Common
Applications
MALDI-MS
2 pm (lateral 
resolution), but 
typically 10 pm
Vacuum
Proteins, peptides, 
lipids, small 
molecules (e.g. 
drugs and 
metabolites).
SIMS 1 pm High Vacuum Trace elements, metals
DESI 40-12 pm Ambient Metabolites, drugs,
LAESI >50 pm Ambient (with the presence of water)
Metabolites, drugs, 
lipids
Table 1.2: Mass spectrometry imaging techniques and their comparative
attributes (Bouschen etal., 2010; Prideaux e ta i, 2012; Nemes 2012; Cornett et 
a i, 2008; Kertesz e ta i, 2008); Laskin e ta i 2012).
Each of the MSI methods has its individual benefits and limitations. However, 
the undeniably valuable information that can be obtained using any of these 
techniques is that of analyte distribution across a sample surface with prior or 
subsequent identification of said analyte.
The concept of MALDI-MS imaging (MSI) of biological tissue was first discussed 
by Caprioli et a i,(1997), with images being generated from an array of mass 
spectra acquired across a sample surface (each pixel corresponds to a mass 
spectrum). This means that if a m/z species is present in a mass spectra taken 
from only certain areas of the sample surface, this will be reflected in pixels and 
as such, an image can be built up to show the actual localisation of the species 
(Figure 1.11).
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Over the last two decades, MALDI imaging has become automated (Stoeckli et 
a i, 1999) and the technology has been continuously evolving. Achievable 
spatial resolution has been improved and it is now possible to obtain images 
down to a lateral resolution of 2 pm, using scanning microprobe MALDI-MS 
(Bouschen et a i, 2010). A range of different samples have been analysed, 
including skin (Hart et a i, 2011), fingerprints (Bradshaw et a i, 2011), tumours 
(Cole et a i, 2011) and whole body rat sections (Stoeckli et a i, 2007). An 
example of the typical “on tissue” MALDI imaging workflow can be seen in 
Figure 1.11. First the tissue to be analysed is sectioned, typically into slices of 
5-20 pm (Benabdellah et a i, 2010; Seeley et a i, 2011) onto a metal target 
plate, or glass slide.
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Figure 1.11: MALDI-MS imaging workflow, from sample sectioning to matrix 
application and MALDI-MSI acquisition. (Adapted from Hanrieder et a i, 2011).
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The sample is then coated with matrix, as described in section 1.4.1.4, Matrix 
Composition and Application. The laser is fired onto the sample surface and for 
each m/z value an image can be generated.
Most recently it has also been possible to produce 3D images from MSI 
acquisitions (Crecelius et a i, 2005; Gillen et a i, 2006; Nemes et a i, 2009). 
This has been performed with SIMS, MALDI and DESI imaging techniques. In 
3D MALDI and DESI imaging experiments the 3D representation is built up 
through the imaging of consecutive tissue sections, taken from different angles 
around the sample (Chen et a i, 2009; Eberlin et a i, 2010). For 3D SIMS 
imaging the process is slightly different, as the primary ion beam that is fired at 
the sample surface causes erosion of the sample. This allows for the 
construction of depth profiles and the ‘stacking’ of 2D images to construct 3D 
images (Fletcher et a i, 2011).
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1.5 Proteomics
Proteomics is an area of scientific investigation which includes the study of 
protein species, be they intact proteins, peptides, amino acids or modifications 
of the three. There are a number of conventional methods that are usually 
employed for proteomic investigations, including electrophoresis, western 
blotting, enzyme linked immunosorbent assay (ELISA), immunohistochemistry 
and MS (often performed after other methods have been used as an initial 
method of separation). Results provided by these traditional methods are 
generally evaluated using visual and phenotypic comparison or may be 
combined with statistical analysis. Methods such as ELISA have been found to 
be extremely useful in detecting species such as cytokines that are present in 
such low quantities that they are often below the limit of detection of mass 
spectrometers (Hoffman et a i, 2008). Mass spectrometry methods are 
however, extremely versatile in the type of samples that can be analysed, often 
require minimal sample preparation and can provide identification and 
localisation information on multiple molecular targets with speed. As a result, 
MS has become increasingly popular in proteomic analyses.
1.5.1 Mass Spectrometry in Skin Proteomics
Different forms of MS have previously been used to analyse and characterise 
skin. The most commonly used form of MS in skin proteomics is that of liquid 
chromatography mass spectrometry (LC-MS). In many cases, skin samples 
undergo homogenisation, protein purification (removal of salts and lipids), gel 
electrophoresis, then, in-gel digestion followed by fractionation; all prior to LC- 
MS analysis, as in the study of Hansell et al., (2008). In this particular study,
36
the human skin had been subjected to blood fluke larvae invasion and LC-MS- 
MS applied to identify peptides related to this process. Subsequent to analysis, 
the mass spectra were processed using MASCOT Distiller. This software de­
isotopes peak lists, leaving only the m/z values of C12 ions that are of use when 
performing database searches. This procedure is important when analysing a 
sample as complex as skin so as to ensure the manageability of data 
processing. One of the biggest disadvantages that LC-MS possesses is the 
inability to analyse an intact sample and the extensive sample preparation that 
is required prior to analysis. MALDI-MS, however, can be performed on tissue 
sections with minimal sample preparation in comparison to LC-MS.
MALDI-MS is one of the most frequently used forms of MS when analysing 
human skin, which may be due to the versatile nature of the application. 
MALDI-MS has been used in the profiling of endogenous proteins within murine 
skin (Huang et a i, 2003). This study provides an example of how MALDI-MS 
can be used to analyse tissue homogenates that have been purified using 
ZipTips (a pipette tip containing solid phase extractant). The purification step is 
an important one as the removal of salts and other endogenous species 
reduces suppression of ionisation of analytes of interest and decreases the 
number of interfering peaks in spectra. A large number of studies such as 
those of Gromov et a i, (2003), Pan et a i, (2009), and Ong et a i, (2010) employ 
MALDI MS for protein/peptide identification, subsequent to excision of spots of 
interest from 2D gels. 2D gel electrophoresis prior to MALDI-MS analysis acts 
as a separation method and means that the MALDI-MS analysis can be more 
specific, thus avoiding the problems associated with the large datasets that can 
be generated in MALDI-MS. In Pan et a i, (2009) the permeability and effects 
of chromium when applied to skin were investigated. Here silver stained spots
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were excised and underwent in-gel tryptic digestion. Trypsin is the preferred 
enzyme for tissue digestion prior to MALDI-MS as it cleaves at arginine and 
lysine residues, and proteins and peptides containing these amino acid residues 
are more easily ionised in MALDI-MS. In a study by Krause et al., (1999) it was 
found that peptides with arginine at the C-terminus were more common than 
those ending in lysine.
Another approach to MALDI-MS analysis of skin is that of direct tissue analysis 
and MALDI-MS Imaging. In a study by Brand et al., (2006) MALDI imaging was 
used to investigate the co-localisation of different anti-microbial peptides within 
frog skin. However, overall, this method of analysis has not been widely 
explored when focussing on skin proteomics. Instead most studies have 
focused on distribution of foreign compounds within skin, as in the case of 
Bunch etai., (2004).
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1.6 Lipidomics
Previously, lipids were commonly analysed using thin layer chromatography 
(TLC). Over the years, TLC has been improved and re-termed as “high 
performance TLC (HPTLC). These improvements include the introduction of 
variable particle size and absorbent materials within the stationery phase, 
allowing for increased selectivity and speed of analysis (Ettre et al., 2008; 
Fuchs et al., 2011). However, MS is becoming increasingly popular in lipidomic 
analysis, particularly for investigation of biological samples/tissues. TLC and 
MS are also now commonly used in combination.
1.6.1 Mass Spectrometry in Skin Lipidomics
There is much evidence to suggest the importance of lipids in biological 
systems and their involvement in disease pathogenesis. The lipid classes that 
appear to have been most thoroughly investigated using MALDI-MS include 
sphingolipids (SLs) and glycerophospholipids (GPLs) (Fuchs et al., 2010). The 
phosphatidylcholine sub-class of GPLs has been indicated as playing a role in 
inflammatory processes. The species lysophosphatidylcholine (LPC) is formed 
where inflammation is induced, as demonstrated in cases of chemical exposure 
(Fuchs et al., 2009), and also as an aspect of disease pathogenesis, as in the 
case of Fabry’s disease (Roy et al., 2006). LPCs can be detected via MALDI- 
MS and are observed in mass spectra as an m/z shift of -52 from the original 
PC signal, which corresponds to the loss of one fatty acyl residue (Arnhold et 
al., 2002; Doering et al., 1999). MALDI-MS has also been used previously to 
analyse skin biopsies taken from patients with Fabry's disease. In this case a
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role for glycosphingolipids in disease pathogenesis was observed (Fujiwaki et 
al., 2002).
A large number of SLs, ceramides and their associated metabolites are 
localised within the stratum corneum and epidermis. These lipid species are 
directly affected as a result of the proteome behaviour within skin (Bartke et al., 
2009) and as such, are also involved in disease pathogenesis (Chalfant et al., 
2005). For example, sphingosine kinase, is activated by proteins such as 
inflammatory cytokines (TNF and IL-1) and growth factors. It has been 
established that sphingosine (Sph), sphingosine-1-phosphate (S1P), ceramide 
(Cer) and ceramide-1-phosphate (C1P) have pivotal roles in apoptosis and cell 
signalling pathways (Pettus et al., 2004). In particular, C1P and S1P are 
claimed to have a role in the inflammation pathway and the arachidonic acid 
cascade (Flolleran et al., 2006; Imokawa et al., 1999; Melnik et al., 1988). Due 
to this behaviour, along with the involvement that glucosylceramides and 
sphingomyelin (SM) have in atopic dermatitis (Di Nardo et al., 1998; Song et al., 
1997; Tornier et al., 2005), there is much information to suggest that there may 
be a lipid response that is specific to sensitization, making this an intriguing 
area of investigation.
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1.7 Study Aims
The main aim of this study is to identify differences in expression of 
endogenous species as a result of skin exposure to sensitizing chemicals. In 
order to facilitate this there are a number of factors to be considered.
Firstly it is necessary to optimise the time periods for which the human skin is 
treated with the irritant and sensitizing chemicals. This can be assessed using 
intact protein analysis and subsequent multivariate statistical analysis.
MALDI-MS methods are then developed for the proteomic and lipidomic 
analysis of human skin. This will allow for the, in-situ, “on tissue” identification 
of endogenous skin proteins/peptides, and lipids.
Through the use of MALDI imaging it should be possible to provide localisation 
information on the species identified and also show differences in regulation 
between the skin samples treated with different chemicals.
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Chapter 2:
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2.1 Introduction
The current, validated method for testing the sensitizing potential of chemicals 
is the murine local lymph node assay (LLNA). This method involves the 
exposure of the animal to a test chemical in question (Basketter et al., 2002). As 
stated in the seventh amendment to the EU directive 76/768/EEC, all testing on 
animals is to be banned within the cosmetic industry. Therefore alternative 
methods of identifying sensitizing chemicals within cosmetic 
ingredients/products must be developed. Previously, the most common 
approach to developing an in-vitro test for chemical sensitizers has involved the 
use of cell based assays (Aleksic et al., 2008; Ashikaga et al., 2006). However, 
Kidd et al., (2007), describe an in-vitro test implementing the use of synthetic 
human skin (EpiDerm FT™) that has been developed and subsequently 
validated for the identification of irritant chemicals (further details are given in 
section1.2.1.2).
MALDI was first used in the analysis of purified protein samples, and brought a 
new method of analysis to the field that required much less sample preparation 
than other forms of MS, such as electrospray ionisation (ESI). MALDI MS 
imaging (MSI) of biological tissue was first described in a study by Caprioli et al. 
(1997). In this study, imaging was used to examine intact proteins in small 
areas of mammalian tissue, mostly rat. Since this first pioneering study there 
have been many examples of MALDI MSI of proteins within biological tissue, 
employing the use of a variety of instruments.
There are a number of reviews discussing the application of MALDI MS and 
MSI for biomarker discovery and investigation. Bakry et al., (2011), discuss the 
use of MALDI and infra-red (IR) imaging in cancer protein biomarker discovery.
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This review highlights the ability of MALDI MS to monitor changes in expression 
of multiple proteins of interest in one experiment. Another recent review by 
Cazares et al., (2011) discusses the impact of MALDI MSI on biomarker 
discovery and its potential for clinical applications. Here, MALDI is compared to 
the more traditional methodologies of immunohistochemistry (IHC) and enzyme- 
linked immunosorbent assay (ELISA).
A specific example of where MALDI-MSI has been used for disease 
classification is that of Djidja et al. (2010), where MALDI-MSI was used in 
conjunction with principal component analysis- discriminant analysis (PCA-DA) 
as a novel method of classifying tissue microarrays of pancreatic tumours. 
Similarly, another recent study by Bonn et al. (2011), discusses the use of 
multivariate analyses, such as hierarchical clustering and PCA in combination 
with “bottom up” and in source decay (ISD) protein ID strategies. This was 
combined with MALDI MSI to investigate prostate cancer.
The following research was aimed at determining whether or not it is possible to 
detect differences between ex-vivo human skin that has been treated with 
chemical irritants, sensitizers, or left untreated, using MALDI MSI.
Differing periods of exposure and subsequent incubation of ex-vivo human skin 
were used to determine optimal conditions for sample differentiation.
Direct tissue profiling was carried out on all samples in triplicate. Spectral data 
was then analysed via PCA-DA, as a valuable tool for data interpretation.
MALDI-MS imaging was performed on treated ex-vivo human skin and 
optimisation attempted.
64
2.2 Materials
Materials used in MALDI matrices: a-CHCA, aniline, acetonitrile, ethanol 
(EtOH), LiCI and trifluoroacetic acid (TFA), purchased from Sigma-Aldrich 
(Gillingham, UK). Carboxymethylcellulose, used for embedding samples, was 
purchased from Sigma-Aldrich (Gillingham, UK). 2-Propanol and formazan 
solution used in the MTT assay, and haematoxylin, eosin and xylene were also 
obtained from Sigma-Aldrich (Gillingham, UK). Dulbecco’s phosphate-buffered 
saline and Dulbecco’s modification of Eagle’s medium, used for tissue washing 
and MTT incubations of human skin, were purchased from Invitrogen (Paisley, 
UK).
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2.3 Methods
2.3.1 Tissue Sample Handling and Treatment
The human skin was obtained from Ethical Tissue, Bradford, UK (licensed by 
the Human Tissue Authority (HTA)) (REC 07/H1306/98), and consisted of fresh 
skin taken from either abdominoplasty or mastectomy surgery earlier that day. 
The human skin was processed within 4 hours after surgery and was 
transported in a plastic container containing phosphate buffered saline (PBS) 
(Invitrogen), stored at 4°C.
The skin was prepared and treated in a category 2 laminar flow hood in the 
primary cell culture laboratory. Skin was cleaned by washing with sterile PBS 
before being cut into approximately 5mm2 squares using a scalpel. Each 
sample with the stratum corneum facing upward, was placed in a well of a 96 
well plate and 40pL of PBS was added to ensure a humid environment was 
maintained, ensuring the skin samples were not fully submersed in the PBS 
solution.
Using sterile filter tips, 1pL of each of the four concentrations (10, 1, 0.1, 
0.01mg/mL) of the cinnamaldehyde, SLS and DNCB solutions were pipetted 
onto individual skin sections and spread across the surface. For each of the 
chemicals at each concentration, applications were performed on triplicate skin 
samples. Five vehicle controls were also prepared (one was discarded due to 
damage). This involved the application of 1 pL of 1:4, olive oil : acetone solution 
to the surface of the skin. Finally, six negative control skin samples remained 
untreated in the wells. All of the aforementioned samples were incubated in a 
humidified environment at 37°C with 5% C02/95% air. The procedures
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mentioned above were repeated for four different time points as follows: 3 and 6 
hour exposure period with no further incubation, a 3 and 6 hour exposure period 
both with subsequent PBS washes and a further 12 hour incubation period in 
Dulbecco’s modification of Eagle’s medium (Invitrogen).
At the end of the final incubation period, all samples were washed with PBS. 
The following steps were performed for each of the skin sections. The skin 
sections were placed into individual blister packs filled with carboxymethyl 
cellulose (CMC) (Sigma-Aldrich). The blister packs were then snap frozen by 
placing the samples on a weighing boat floating on liquid nitrogen. The 
embedded samples were then removed from the blister packs and placed into 
labelled petri dishes in the -80°C freezer. All frozen samples were stored in 
labelled sample boxes in the -80°C freezer. All human tissue remains and 
waste materials that had been in contact in any way with human tissue was 
placed inside a biohazard bag in the -80°C to await disposal by incineration. 
Any non-disposable implements were disinfected in bleach.
2.3.2 MTT Assay on Human Skin Samples
300pl_ of 1 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) media was pipetted into each well of a 24-well plate. The skin samples 
were then transferred to the well plate and placed into an incubator (37°C, 5% 
C02/95% air) for 3 hours. After completion of the MTT incubation the media 
was aspirated from the wells using an air displacement pipette. The skin 
samples were then washed by the application and aspiration of Dulbecco's 
PBS, (Invitrogen), repeated twice. The skin was then transferred to a fresh 24-
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well plate and immersed in 2mL of isopropanol (Sigma). The well plates were 
then sealed using parafilm and left for 2 hours at room temperature to mix 
gently on a plate shaker. For each piece of skin tissue, 2 x 200pL of the blue 
formazan solution was aliquoted into a fresh 96-well plate. Isopropanol was 
used as a blank solution and placed in the top and bottom rows of the well 
plate. The MTT enters the cells within the tissue and is largely reduced in the 
mitochondria to produce a purple formazan product. Once the cells were 
solubilised via the addition of isopropanol, the purple reduction product is 
liberated, detected and measured using a spectrophotometer. The level of 
colour observed is proportional to the number of viable cells, as the 
mitochondrial enzymes would not function in the event of necrosis (Lui et al., 
1997; Maioli etal., 2009).
The precise layout of the chemicals and solutions in the 96-well plates used in 
the MTT experiments can be seen in Figure 2.1. The absorbance of the 
solutions was then measured spectrophotometrically at a wavelength of 570nm 
(Tornier et al., 2005). Absorbance values for each sample were entered into an 
excel spreadsheet provided by MatTek Corp. (Ashland, MA). This spreadsheet 
determined the percentage viability of the tissues, the results of which can be 
seen in Figure 2.2.
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2.3.3 Intact Protein Analysis (Profiling)
12|jm tissue sections were cut using a cryostat Leica 1850 UV Leica, set to - 
20°C, and mounted onto thin aluminium plates or indium tin oxide (ITO) glass 
slides. These were then washed in 70% ethanol for one minute, followed by a 
minute in 90% ethanol. Both ethanol solutions were stored at -20°C prior to 
use. This step aids in the removal of salts that may suppress mass 
spectrometric detection, as well as fixing the protein (for which the cool 
temperature is appropriate). Sections were then left to air dry. 25mg/mL 
sinapinic acid (Sigma) in 50:50 acetonitrile (Sigma): water with 0.1% TFA 
(Sigma) was prepared as a matrix solution. A 20-30 minute sonication step was 
required to ensure full solubilisation of the sinapinic acid. Matrix was spotted 
onto the tissue sections manually. This was implemented using an air 
displacement pipette with volumes of between 0.3pL and 1pL depending on the 
size of matrix spots required. Two layers of matrix were added, allowing the 
solution to air dry after each application.
The mass spectrometers used in these experiments were a Voyager De Pro™ 
(Applied Biosystems/MDS Sciex, Concord Ontario, Canada) MALDI-TOF, with 
an Nd-YAG laser (suitable for low molecular mass proteins), and a Voyager De 
St r ™ (Applied Biosystems/MDS Sciex, Concord Ontario, Canada) MALDI- 
TOF. Both instruments were operated in linear mode, using a delay time of 750 
nsec. 200 laser shots were fired per spectrum, at an intensity of 2900 (arbitrary 
units).
The mass spectrometer was successfully calibrated using a mixed protein 
calibration standard of apomyoglobin, thioredoxin and insulin (PE Biosystems,
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Foster City, CA, USA), prior to the analysis of samples. The calibration was 
performed under the parameters described above.
2.3.4. Intact Protein Analysis (Imaging)
The washing steps were performed as for the profiling experiments described in 
section 2.3.3. For initial multiple sample imaging, 5 mg/mL sinapinic acid in 
50:50 acetonitrile: water, 0.2% TFA was prepared as a matrix solution. A 
sonication step was required for solubilisation and matrix was used at a lower 
concentration than in the profiling experiments to prevent blockage in the 
sample spraying instrument. The matrix was applied using the SunCollect™ 
(KR Analytical, Sandbach, UK)) automated sprayer. 5 layers of matrix were 
applied using the stepped, slow speed mode (non continuous) at the following 
flow rates: 1.5 pL/min, 2.5 pL/min, and a final three layers at 3.5 pL/min. The 
spraying needle was at a distance of 1 cm from the sample surface. The 
instrument capillaries were flushed with acetonitrile before and after the 
spraying of matrix. After a successful application of matrix, the coverage 
appeared homogenous across the whole sample.
The Portrait® 630 Spotter (LABCYTE™), acoustic spotter (Aerni et. al., 2006) 
was used for the application of sinapinic acid concentrations of 10 and 20 
mg/mL. Matrix was deposited onto the tissue sections with a distance of 200 
pm between each spot and with one droplet being applied per spot. 50 layers 
of matrix were deposited onto the sample surface.
The mass spectrometers used in imaging experiments were a modified Voyager 
De Pro™ (Applied Biosystems/MDS Sciex, Concord Ontario, Canada) MALDI- 
TOF, with an Elforlight UV-FQ Nd-YAG laser (suitable for low molecular mass
71
proteins), and a Voyager De STR™ (Applied Biosystems/MDS Sciex, Concord 
Ontario, Canada) MALDI-TOF. Both instruments were operated in linear mode, 
using a delay time of 750 nsec. 200 laser shots were fired per spectrum, at an 
intensity of 2900 (arbitrary units).
The mass spectrometers were successfully calibrated using a mixed protein 
calibration standard, prior to the analysis of samples. The calibration was 
performed under the parameters described above.
2.3.5. Data Processing
All spectral data were processed using SpecAlign™ software (Wong et al., 
2005). This software was used to generate an average spectrum and peaks in 
all spectra being analysed were subsequently aligned to the position of peaks in 
that average spectrum, and all spectra were normalised against the total ion 
count (TIC). All images were processed using Biomap Software 3.7.5.5 
(Novartis, Basel, Switzerland) (Stoeckli et al., 2002).
For statistical analysis, PCA-DA was performed using MarkerView™ software 
(ABSciex, Cheshire, UK) (Ivosev et al., 2008).
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2.4 Results
2.4.1 MTT Assay
MTT assays were carried out to confirm the cellular viability of the human skin 
samples after chemical treatment. A separate MTT assay was carried out for 
three of the four time points, as shown in Figure 2.2. The 3 hour exposure, 12 
hour incubation time point MTT assay was not performed due to insufficient skin 
samples. It was important however to perform the assay for as many different 
time points, especially for the longest duration, as the tissue viability may 
decrease over time.
The MTT results show that all of the samples have a relative viability of >50%. 
There is a large amount of variability between different samples in all three of 
the graphs shown in Figure 2.2. The data also shows inconsistency within the 
replicates of the same sample type, as represented by the large error bars on 
each of the bar graphs. These discrepancies may be explained by the differing 
size of the skin samples that were treated and analysed. This is something that 
can be easily resolved for future experiments through the use of a tissue punch, 
to ensure equal sample sizes. Another problem with the results presented in 
Figure 2.2 is that some samples appear to have a high relative percentage 
viability due to the inconsistency caused by differing sample sizes. The 
10mg/ml_ DNCB treatments were discontinued in further experiments as 
abnormal discolouration of the affected skin sections was observed following 
treatment with DNCB at this high concentration, which could be attributed to 
cytotoxicity at this DNCB concentration.
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Figure 2.2: The average percentage viability of the differently treated samples.
(A) MTT results following 3 hour exposure, with no further incubation time point.
(B) MTT results following 6 hour exposure, no incubation time point. (C) 6 hour 
exposure, 12 hour post incubation time point.
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The MTT results in Figure 2.2 indicate that the tissue treated with 10mg/mL 
DNCB still had a relative viability >50%. The viability calculation assumes that 
the untreated negative control sections are 100% viable, which is unlikely to be 
the case and this would lead to an overestimate of cell viability. This is due to 
some cell death that would have occurred from the point at which it was 
excised, whether skin was treated or not. Therefore, cell death due to excision, 
delay time and transport etc. should be considered as a possible cause of 
variation.
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2.4.2 Principal Component Analysis - Discriminant Analysis 
(PCA-DA)
Direct tissue profiling was carried out on serial sections of samples. Example 
spectra from this analysis can be seen in Figure 2.3. Each of the four spectra 
shown in Figure 2.3 reveal the existence of unique species as some peaks are 
present only in spectra relating to one sample type. This is something that is 
more easily highlighted in the PCA-DA results, as some peaks are not seen in 
the spectra in Figure 2.3 without zooming in on specific m/z areas. The 
detection of some signals common to all 4 spectra is also clear (e.g. the peak 
seen at approximately 33150 m/z). Here the peak intensity varies between each 
different spectrum, this could be due to the difference in matrix crystallisation 
and thus ionisation from spot to spot.
There is evidence of peak shift in the spectra in Figure 2.3, where peaks that 
are likely to represent the same species display a shift in m/z. In order to 
correct for this, all spectra were processed using SpecAlign™ software (Wong 
et al., 2005) to correct for peak shift and assign peaks of interest. Spectra were 
then suitable for further analysis and processing. Using the spectra taken from 
the direct tissue profiling experiments, peak lists were generated as text files 
and imported into Markerview™ software (Ivosev et al., 2008). PCA-DA was 
then performed on all of the samples for a particular time point, with each 
sample type having 9 replicates to ensure reproducibility of results. The 
software generates two main plots that are of interest, the loading plot which 
can be seen on the right hand side of each of the Figures 2.4, and 2.6 - 2.8, 
with the score plot to the left.
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Figure 2.3: Mass spectra produced from the direct tissue profiling of human skin 
treated as follows: A) untreated (negative control), B) vehicle control (1:4, olive 
oil : acetone solution), C) treated with 10mg/mL SLS, D) treated with 10mg/mL 
cinnamaldehyde. The method of analysis is described in section 2.4.1.
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Figure 2.5: Processed Markerview data from skin samples that have undergone 
3 hours of chemical exposure, without post incubation, taken from Figure 2.4 
and put through Principal Component Variable Grouping (PCVG) software. The 
different colours and shapes represent different groups of variable m/z values 
and are directly comparable to the loading and score plots seen in Figure 2.4 
(numbers indicate m/z values).
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Figure 2.9: Processed Markerview data from samples that have undergone 6 
hours of chemical exposure, with a further 12 hour incubation, taken from 
Figure 2.8 and put through PCVG software. The different colours and shapes 
represent different groups of variable m/z values and are directly comparable to 
the loading and score plots in Figure 2.8.
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The results in Figure 2.4 show that the replicates within each sample type are 
grouping to a certain extent for the skin samples that were chemically exposed 
for 3 hours, without post incubation. The separation of the treated and 
untreated samples is not clear, whilst the DNCB exposed tissue has grouped 
and is localised within a quadrant on its own, the cinnamaldehyde samples are 
in the same position as the negative control. This indicates that there is little 
detectable difference in the protein content following DNCB exposure for 3 
hours compared with the negative control. Due to the poor separation of 
samples the PCVG plot in Figure 2.5 is not particularly useful in identifying 
groups of species that are specific to a sample type, merely those that are 
common to all of the spectra.
The PCVG plots shown in Figures 2.5 and 2.9 are directly comparable to their 
corresponding PCA plots in Figures 2.4 and 2.8, respectively. The PCA results 
highlight which individual samples and sample groups are most different from 
each other and indicate outlying species that are not common to all samples. 
The PCVG plots show a number of different groups of m/z values that are 
represented by different coloured/shaped markers. In a particular group there is 
a variable that is common to all of the members (i.e., they are all, in some way, 
similar to each other) (Ivosev et a i, 2008). This may be, for example, that each 
of the m/z species in a particular group are most prevalent in a specific mass 
spectrum, or spectral repeats belonging to a specific sample type (in this case 
all of the spectra from a treated, or untreated skin sample).
The loading plot of the 3hour exposed, 12 hour post incubation samples (Figure 
2.7), is of a similar shape to that seen after the 3 hour exposure only 
experiment (Figure 2.4), although there are more outlying species. The 
grouping of the replicates within the different samples allows the treated
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samples to be distinguished from controls. The sample distribution across the 
score plot indicates that the vehicle control and the negative control are not in 
the same quadrant and therefore are showing significant dissimilarity in the 
skin’s response.
The most promising PCA-DA results that were generated from the spectra of 
the 6 hour exposure, 12 hour post incubation experiment can be seen in Figure 
2.8. The sample types have all separated well with those treated with the 
strong sensitizer (DNCB) in one quadrant, both concentration levels of the weak 
sensitizer (cinnamaldehyde) together in another, both concentrations of the 
irritant (SLS) in the third quadrant and the two controls in the final quadrant. 
This demonstrates that the separate irritant and sensitizer responses can be 
distinguished based upon m/z values. The weak and strong sensitizers can also 
be differentiated at this time point.
One factor that may be of concern when considering the grouping is whether it 
is due to any species that are detected as a result of cell death in the tissue. 
This makes it even more important to identify the m/z values that are outlying, 
as if they are confirmed as being components of cell death they could be added 
into an exclusion list and removed from the peak lists that are imported into the 
PCA-DA analysis. Another point of consideration is that due to the skin having 
been excised a period of time before the experiments were performed, there will 
be a certain amount of cell death occurring in all tissue sections. If this is the 
case it may be possible that the m/z values attributable to cell death are in the 
large central cluster of species (within the loading plots) that are common to all 
of the spectra from various sample types. This could be established by looking 
for the m/z of the proteins related with cell death, such as tumour necrosis
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factor proteins (TNF), within the statistical plots (this is possible when viewing 
results whilst in loaded in the software).
The PCVG results (fig 2.8) from this experiment are of greater use, as the 
different variable groups are more specific to the areas in which the sample 
groups are located. For example, the variable group that is represented by the 
dark green triangles is specific to the area in which the DNCB treated samples 
are located. This piece of software should therefore make it easier to identify 
possible biomarkers. The use of this program does however need to be 
optimised so that it is easier to pick out the variable groups as the PCVG plots 
in Figures 2.5 and 2.9 are of complex appearance.
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2.4.3 Multiple Sample MALDI-MS Imaging
MALDI imaging experiments were carried out on multiple tissue samples at one 
time, for ease of comparison. Initial images were acquired at a spatial resolution 
of 300pm x 300pm (an example is shown in Figure 2.10), with the aim of 
reducing the acquisition time, so that it was be possible to image multiple 
samples in one run.
Negative
Control
Vehicle
Control
treated
Cinnamaldehyde
treated
Figure 2.10: MALDI MS image of human skin, m/z range spanning 8419 to 
8432. The scale bar on the right hand side of the image shows the relationship 
between intensity (counts) and colour as seen on the image.
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The image in Figure 2.10 shows the up-regulation of a species at m/z 8419 to 
8432, thought to correspond to an intact protein. However poor mass accuracy 
was observed and it is not possible to identify intact protein species through 
relative molecular mass (RMM) alone. Whilst the image does display difference 
between the samples, localisation of the species within each section is not 
clear. In an attempt to improve image quality, matrix optimisation experiments 
were performed.
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2.4.4 Matrix Optimisation for Imaging
A number of experiments have been performed in an attempt to optimise the 
conditions for MALDI imaging of intact proteins. The aim of these experiments 
was to improve peak resolution, signal to noise (S/N) and overall detection of 
peaks.
2.3.4.1 Concentration of Matrix
Initial images were acquired prior to matrix application using the SunCollect 
automated sample sprayer (KR Analytical), as in the multiple sample image in 
Figure 2.10. However, this method of matrix application limited the matrix 
concentration to 5 mg/mL. In order to increase the concentration of matrix 
applied, the Portrait® 630 Spotter (LABCYTE™), acoustic spotter was used. In 
Chaurand et a i, (2008), where MALDI imaging of intact proteins was 
performed; the Portrait was used to apply concentrations of 20 mg/mL Sinapinic 
acid to tissue sections. Here, two concentrations of sinapinic acid were 
compared to ascertain the optimum conditions for imaging experiments.
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Figure 2.11: MALDI-MS image of m/z 13989 in human skin sections coated 
with (A) 20 mg/mL sinapinic acid (SA), dissolved in 50 % ACN, 50% deionised 
water, 0.2 % TFA, and (B) 10 mg/mL sinapinic acid (SA), dissolved in 50 % 
ACN, 50% deionised water, 0.2 % TFA . The scale bar on the right hand side of 
the image shows the relationship between intensity (counts) and colour as seen 
on the image.
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A) and 10 mg/mL (cone B).
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Figure 2.13: Plot displaying the relationship between concentration of matrix 
and peak intensity, with data generated from skin coated with 20 mg/mL 
sinapinic acid, shown in blue, and 10 mg/mL shown in red.
There is no significant difference in the signal intensities of peaks detected with 
the different concentrations. Whilst peaks at certain m/z are more intense using 
20 mg/mL (m/z 6,436, 10,208, 15,131), others are more intense when using 10 
mg/mL concentrations (8,566, 14,012). Average m/z was used here due to the
lower peak resolution and mass accuracy routinely observed at higher
molecular masses.
■ 20 mg/ml
■ 10 mg/mL
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2.4.4.2 Ionic Matrix
The first of these experiments involved the addition of aniline, in concentrations 
that are equimolar to that of the matrix used (sinapinic acid in this case). In a 
study by Franck et al., (2009), the addition of aniline to SA matrix solutions has 
been found to improve signal to noise ratio and overall peak intensity of proteins 
detected in tissue. However, in the experiments reported here, the human skin 
section coated with the aniline containing matrix (Figure 2.14A) shows reduced 
protein detection when compared with the tissue coated with the aniline free 
matrix (Figure 2.14B).
Figure 2.14: MALDI image of untreated human skin that has been spotted with: 
(A) 10 mg/mL sinapinic acid (SA), dissolved in 50 % ACN, 50% deionised 
water, 0.2 % TFA, with added aniline at a concentration equimolar to that of 
SA; (B) 10 mg/mL SA, dissolved in 50 % ACN, 50% deionised water, 0.2 % 
TFA, with no added aniline. The image is of m/z 11386.
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Figure 2.15: Stacked spectra from untreated human skin sprayed with different matrices, with (A) and without aniline (B).
When data acquired with and without aniline was investigated further, it would 
appear that the addition of aniline causes an increase in signal at certain m/z 
values, but a decrease at others. Figure 2.15, shows stacked spectra, 3 of 
which have been taken from each of the two concentrations. The spectra have 
been aligned and normalised against the total ion count (TIC) using the data 
processing tool; SpecAlign (Wong et al., 2005).
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Figure 2.16: Plot displaying the relationship between the addition of aniline to 
matrix and peak intensity. Data generated from sinapinic acid/ANI coated skin 
is shown in red, with the sinapinic acid alone, in blue.
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Figure 2.17: MALDI images of intact proteins in untreated human skin, 
generated using the Voyager De-STR (Applied Biosystems), MALDI-TOF. 
Images (A)-(D) are of unknown species, with m/z imaged labelled on each 
image. (E) displays an overlay of images generated at m/z 10235 (red), and 
m/z 14005 (green).
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After optimising the sample preparation/matrix composition, the images in 
Figure 2.17, show improvement when compared to initial images. The optimised 
sample preparation procedure, combined with the acquisition of the image at a 
spatial resolution of 150 pm has, to an extent, enabled the visualisation of 
species localisation within the cross section of skin sections. This is 
emphasised in the image overlay in Figure 2.17E, where a species of m/z 
10,235 (in red) is shown to be ubiquitous within human skin, unlike the species 
at m/z 14,005 (in green), which is predominantly distributed within the upper, 
epidermal region.
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2.5 Discussion
2.5.1 MALDI-lmaging and Direct
Spectra generated from direct tissue profiles, has been found to be of better 
quality than that produced through MALDI imaging. This is due to a number of 
reasons. Firstly, the matrix was manually pipetted onto tissue for direct tissue 
profiling, whereas for imaging experiments, matrix was sprayed to provide an 
homogenously crystallized layer of matrix. Due to technical limitations of the 
automated sprayer this meant that a much higher concentration of sinapinic 
acid could be applied to samples not being imaged. As proteins are of high 
molecular mass, they can benefit from being imaged with a higher concentration 
of matrix such as sinapinic acid (Caldwell and Caprioli, 2005), as the matrix ions 
must be in excess to ensure optimal ionisation of the analyte.
The attempted solution to this problem was to use the Portrait 360 spotter, 
which is capable of depositing higher concentrations of matrix due to the 
absence of capillaries etc. required for application. This was used along with 
improved spatial resolution, to enhance overall image quality. However, when 
lowering the spatial resolution of images, time constraints are introduced. This 
meant that it was not feasible to acquire one image of multiple samples. 
Spectral quality from images was also improved; however, it was still not as 
effective as manual profiling. This may be due to the impossibility of setting the 
image to fire the laser directly over the matrix spots laid by the Portrait.
A fundamental issue with intact protein data acquired was that it is not possible 
to identify proteins based upon relative molecular mass (RMM) alone. This is
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due to the possibility of there being more than one species present within the 
m/z range over which an intact protein peak may be detected. Another issue 
encountered was low mass accuracy, caused in part by unacceptable peak 
resolution. One possible reason for the poor shape of peaks (seen in Figures 
2.3 and 2.4) is that whilst the detector is in linear mode, ions of the same mass 
are not reaching the detector at the same time. This is due to a difference in 
their kinetic energy that has not been resolved in the drift tube and ultimately 
resulted in broadening of peaks. This is a common limitation and can be 
observed in other studies, where alternative methods of identification have been 
employed. One example of this has been shown by Stoeckli et al. (2001), 
where localisation of intact protein within tumour sections was achieved. 
Spectra in this study also demonstrate broadened peak shape. Thus, 
identification of species imaged was accomplished via HPLC fractionation of the 
sample to isolate the protein of interest. This was then digested with trypsin on 
a MALDI target plate, and a database search performed on subsequent MALDI 
MS/MS of tryptic peptides. More recent studies have shown that it is also 
possible to perform “on tissue” digestion and identify tryptic peptides via MALDI- 
MS/MS in-situ (Shimma et al., 2006; Groseclose et al., 2007). Shimma et al., 
(2006), employed the use of a chemical inkjet printer to apply trypsin to a 
denatured tissue section. This was then left to digest for 12 hours prior to 
matrix application and subsequent MSMS identification of tryptic peptides, using 
MALDI Quadrupole Ion Trap (QIT) TOF.
It is also important to note that even with improved peak shape and mass
accuracy it would still not be possible to identify proteins based upon RMM
alone. This is due to the existence of isobaric protein species (of the same
RMM) that cannot be separated in their intact form. This is also true for all other
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m/z species where there are isobaric molecules present. This issue is 
addressed in chapters 3 and 4.
2.5.2 PCA-DA Data
One of the significant observations that can be made when using PCA-DA to 
look at the most effective time point for treatment with chemical irritants and 
sensitizers, is that DNCB treated samples group differently to cinnamaldehyde 
treated samples. This is something that could be explained through the 
different mechanisms by which sensitizers act as they vary in potency. This 
difference in behaviour between groups of sensitizers was discussed by 
Basketter et al. (2007). This study found evidence to suggest that chemicals 
which are stronger irritants are also stronger sensitizers. In the PCA-DA results 
of Figure 2.8 the DNCB treated samples are grouped in a quadrant that is 
localised between the quarters in which cinnamaldehyde and SLS are grouped. 
This may be due to the fact that the DNCB is both an irritant and a sensitizer. 
Referring to the findings of Basketter et al. (2007) this may suggest that in 
future experiments the stronger sensitizers will group closer to the bottom right 
of the PCA-DA plot (closer to the irritant samples and further away from the 
controls), whereas the weaker sensitizers may group closer to the controls than 
the irritant treated samples.
Sensitization occurs when chemical allergens form irreversible covalent bonds
with proteins (Aleksic et al., 2007). This means that the protein adducts formed
during sensitization are of different mass, dependant on the chemical sensitizer
applied. Therefore the PCA-DA from cinnamaldehyde and DNCB treated skin
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samples could be explained by the difference in m/z of their protein adducts. It 
may be possible to confirm this theory through analysing a greater number of 
chemical sensitizers and attempting to identify m/z ratios that correspond to the 
protein adducts they form. If this is found to have a profound effect on the PCA- 
DA plots it would be possible to exclude the specific m/z values of the protein 
adducts from the peak lists imported into the Markerview™ software and then 
re-evaluate the results.
As mentioned in the results section 2.3.2, the PCVG result plots are very 
complex in appearance making them difficult to interpret. Some ways in which 
it may be possible to combat this problem may be to alter intensity thresholds or 
decrease the number of variables being looked for.
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2.5 Conclusion
PCA-DA of replicate mass spectra shows clear differentiation between skin 
treated with sensitizing and irritant chemicals and control skin samples. This 
form of statistical analysis was primarily used to indicate the most suitable time 
points for treatment of the human skin. The only information provided in these 
spectra was the RMM of the intact species within skin and this was not sufficient 
for positive protein identification.
It has been possible to distinguish between layers of skin in MALDI-MS images 
of m/z signals within an intact protein mass spectrum.
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Chapter 3:
Proteomics, Peptide Analysis
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3.1 Introduction
When using MS there are two main routes via which a protein may be identified; 
high mass accuracy intact analysis (“Top down proteomics”), and peptide 
analysis subsequent to protein digestion (“Bottom up proteomics”). The route 
chosen for this study was a “bottom up” method, of protein digestion and 
subsequent tandem MS of peptides. Digestion of peptides for MALDI-MS 
analysis can be performed “in solution”, where trypsin is added to a sample that 
has been homogenised and in some cases purified, and then spotted onto a 
target plate, before being coated with matrix. However, the route taken in this 
case was that of “on tissue”, in-situ tryptic digestion, with the tissue sample 
remaining intact. There are a number of ways in which the trypsin and 
subsequent matrix solutions have been applied directly onto tissue sections. 
Groseclose et a i, (2007) describe how trypsin and matrix solutions can be 
applied directly on to tissue using a ChlP-1000ink-jet spotter (Shimadzu Co., 
Kyoto, Japan). In the study of Djidja et a i, (2010) the trypsin and matrix 
solutions were sprayed onto the target using a SunCollect™ automatic sprayer 
(SunChrom, Friedrichsdorf, Germany). There are advantages and 
disadvantages to both methods of matrix coverage as the ink-jet spotter cannot 
give the homogenous coating of matrix that produces such representative 
images. It does however allow for the use of a higher concentration of matrix 
than is possible with an automatic pneumatic nebuliser, or sprayer, which relies 
on fine capillaries that would get blocked by matrix crystals from higher matrix 
concentrations. This study has employed the use of the automatic sprayer 
along with another modification to the traditional tryptic digest, the addition of a 
detergent. Djidja et a i, (2009) describes how the addition of a detergent to
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trypsin solution, prior to sample coverage can significantly improve the yield of 
peptides detected.
When employing the use of mass spectrometry for proteomic studies, there are 
several approaches that may be adopted. For analyses of pure proteins it may 
be possible to achieve identifications via in source decay of the intact molecule 
(Debois et a i, 2010), referred to as “Top Down” proteomics. The processing of 
this data may be done manually, or with the use of a search engine that enables 
“no enzyme” searches, such as MASCOT. However, the more common 
approach, as mentioned previously, is through enzymatic digestion, MS/MS, 
and peptide sequencing (“Bottom up”). Typically, MS/MS data are processed 
for peptide identification, using dedicated search engines, such as ‘X! Tandem’ 
(Titulaer, 2013), and ‘MASCOT’ (Perkins et a i, 1999). These search engines 
search for matches to peptide sequences in protein databases, the most 
common of which being ‘SwissProt’ and NCBI. When it is not possible to make 
identifications via a database search, De Novo sequencing may be performed. 
The most commonly observed ions that are observed in a low energy MS/MS 
spectrum and may be used for sequencing are from the b and y series. These 
ions are produced when the amide bonds along the peptide backbone are 
broken in fragmentation. The mass differences observed between these ions in 
spectra are representative of the amino acid residues within a peptide. Other 
series of ions may also be detected in MS/MS, generated from high energy CID, 
these include a, d, v and w ions. These additional ions are attributable to the 
side chains of a peptide and can make the interpretation of a peptide MS/MS 
spectrum more difficult to interpret (Ma etal., 2012).
109
The aims of the work reported in this chapter were to optimise the conditions for 
a "bottom up" on-tissue proteomics strategy for the analysis of human skin 
whilst facilitating the characterisation of endogenous peptides/proteins.
Images of peptides, generated from the on-tissue digests of human skin, were 
acquired at 150pm to provide localisation information. After optimisation of 
imaging, 30 pm images were acquired with the purpose of gaining more 
discreet distribution profiles for peptides detected. Ion mobility separation was 
used to improve the certainty of peptide identification.
Finally, multivariate statistical analysis was performed on spectra taken from 
regions of human skin with the aim of highlighting differences between peptide 
expression in the epidermis and dermis.
110
3.2 Materials
All materials used in the MALDI matrix including: alpha-cyano-4-hydrocinnamic 
acid (a-CHCA), aniline, ACN, and TFA, were purchased from Sigma-Aldrich 
(Dorset, UK). The CMC used to embed the human skin samples was also 
purchased from Sigma-Aldrich (Dorset, UK). The HPLC grade ethanol and 
chloroform solutions that were used in tissue washing procedures were 
purchased from Sigma-Aldrich (Dorset, UK). Ex-vivo human skin was obtained 
from Ethical Tissue, Bradford University (licensed by the human tissue authority 
(HTA), and handled as described in chapter 2 (with materials stated in section
2 .2 ). Porcine derived trypsin was purchased in lyophilised form, from Promega 
(Southampton, UK) and the detergent used in trypsin solutions, Octo-a1 p 
glucoside was purchased from Sigma-Aldrich (Dorset, UK). The polyethylene 
glycol (PEG) solution used for instrument calibration was purchased from 
Sigma-Aldrich (Dorset, UK))
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3.3 Methods
3.2.2 Human Skin Tissue Sample
The human skin was obtained from Ethical Tissue, Bradford, UK, licensed by 
the Human Tissue Authority (HTA) (REC 07/H1306/98). All human tissue was 
handled and stored in the appropriate ethical manner. Negative, untreated 
controls and controls treated with only the acetone: olive oil (4:1) vehicle were 
also incubated alongside the chemical irritant and sensitizer exposed samples 
(as described in Chapter 2, section 2.3.1). At the end of the incubation period, 
all samples were washed with PBS, before being placed into individual blister 
packs filled with CMC. The blister packs were then snap frozen on liquid 
nitrogen as described in chapter 2. An MTT assay (Tornier et al., 2005) was 
performed on replicate samples at the end of the experiment to determine 
tissue viability (the full MTT methodology is given in chapter 2, section 2.3.2).
3.2.3 Tissue Preparation and Matrix Deposition
12pm tissue sections were cut using a cryostat (Leica 1850 UV, Leica, 
Microsystems, UK) and thaw mounted onto poly-lysine coated glass slides 
(supplier). Sections were stored in a sealed container at -80°C prior to analysis. 
It was necessary to include a tissue washing step prior to analysis in order to fix 
the tissue and remove excess salt and other impurities from the skin. The 
mounted tissue sections were washed in 70% ethanol for one minute, followed 
by one minute in 90% ethanol. Both ethanol solutions were stored at -20°C 
prior to use. This step aids in the removal of salts that may suppress mass
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spectrometric detection as well as fixing the protein (Franck et a i, 2009). Slides 
were then submersed in chloroform for 5 seconds to remove lipids, which may 
interfere with peptide detection due to similar mass values.
Porcine derived trypsin (Promega) was dissolved in 50mM NH4HCO3 
(approximately pH8 ) to give a 20 pg/mL solution. 1 pL of the detergent, 10 mM 
Octo-a1 p glucoside (Sigma-Aldrich) was then added to the trypsin solution to 
assist solubilisation of proteins. The trypsin was applied to the skin section 
using the SunCollect™ (KR Analytical, Sandbach, UK)) automated sprayer. 
Five layers of trypsin were applied at the following flow rates: 1.5 pL/min, 2.5 
pL/min, and a final three layers of 3.5 pL/min. The instrument capillaries were 
flushed with deionised water before the spraying of trypsin and then with 1 0 0 % 
acetonitrile (Sigma-Aldrich) afterwards. The sections were then placed in a 
chamber (humidified with 50:50 methanol: water) and left to incubate for a 
minimum 2 hour period at 37°C, 5% C02/ 95% air.
1 ml_ of 5 mg/mL a-CHCA in 50:50 acetonitrile: water, 0.1% TFA, 2.4 pL aniline 
(Sigma-Aldrich) was prepared as a matrix solution. A sonication step was 
performed after the addition of acetonitrile and then again after the addition of 
aniline. The matrix was then sprayed onto the tissue section(s) using the same 
method as for the application of trypsin. The Suncollect instrument was flushed 
with 1 0 0 % acetonitrile after completion of the run.
3.2.4 Direct On-tissue MALDI-MS/MS
Initial MALDI-MS and MS/MS were acquired from the in-situ skin sample 
surface using a modified MALDI-Q-TOF, Q-Star Pulsar-/ ™(Applied
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Biosystems/MDS Sciex, Concord Ontario, Canada). These modifications have 
been reported elsewhere (Trim et al., 2010). Data was acquired in positive 
mode using an NdYV04 laser (Elforlight "SPOT"), operated at 5 kHz repetition 
rate and 80% laser energy (approximately 4.2 pJ).
Further MALDI-MS/MS spectra were acquired from the in situ skin sample 
surface using a MALDI HDMS SYNAPT G2™ system (Waters Corporation, 
Manchester, UK). Data was acquired in positive mode using a 1 KHz Nd:YAG 
laser at approximately 3 pJ (equivalent to 150 arbitrary units on the instrument). 
Initially, a TOF MS spectrum was acquired and then calibrated using the 
lockmass facility in MassLynx and a sodiated PEG solution (Sigma-Aldrich 
(Dorset, UK)). Peaks from this MS trace were then selected for MS/MS where 
the precursor ions were fragmented in the transfer cell subsequent to ion 
mobility separation. All MS/MS were lockmassed to the precursor m/z from the 
original, calibrated spectrum. All product ion spectra were centroided before 
being put through MASCOT to search the UniProt database for matches.
3.2.5 MALDI-MS Imaging
MALDI-MS images were acquired from the in situ skin sample surface using a
MALDI HDMS SYNAPT G2™ system (Waters Corporation, Manchester, UK).
Images of 150 pm spatial resolution were acquired sequentially at laser power
of approximately 3 pJ (equivalent to 150 arbitrary units on the instrument).
Multiple images were run under one project name in Masslynx, allowing for
them to be converted for viewing in Biomap, either individually or together
(showing multiple sections in one Biomap image). Data was acquired over an
m/z range of 700-2500. 30 pm MALDI images were also acquired using the
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Synapt G2 instrument. These were acquired at a lower laser power of 2.1 pJ 
(equivalent to 1 0 0  arbitrary units on the instrument), in order to obtain a smaller 
laser spot size. The high spatial resolution images were run on only a strip of 
cross sections of human skin, due to time restrictions. This was performed on 
DNCB treated and untreated skin samples alike. Data was acquired over an 
m/z range of 700-2500. Ion mobility settings, such as wave velocity were 
optimised prior to each acquisition.
3.2.6 Data Processing
The majority of images were processed using Biomap Software 3.7.5.5 
(Novartis, Basel, Switzerland) (Stoeckli et al., 2002). Some images generated 
using the Synapt MALDI-HDMS (Waters Corp.) were also processed using the 
Waters High Definition Imaging (HDI) software package.
Prior to statistical analysis, all spectral data were processed using SpecAlign™ 
software (Wong et a i, 2005). This software was used to generate an average 
spectrum and peaks in all spectra being analysed were subsequently aligned to 
the position of peaks in that average spectrum, and all spectra were normalised 
against the TIC. Peptide spectra for statistical analysis were then processed 
using mMass, an open source mass spectrometry tool (Strohalm et a i, 2008 
and 2010). mMass was used to deisotope and peak pick the mass spectra.
PCA-DA was performed using MarkerView™ software (ABSciex, Cheshire, UK)
(Ivosev et a i, 2008). Subsequent to this MatLab, version 7.6.0 324 (R2008a)
(The MathWorks, Inc., 24 Prime Par Way, Natick, MA, USA) was also used on
the same data sets to provide further information. When using MatLab, the
Eigenvector, PLS_Toolbox (Eigenvector Research Inc., Wenatchee, USA) was
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used. This software was used as an interface to input the data into MatLab and 
select the type of statistical analyses required, enabling the use of MatLab 
without the need for script writing.
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3.4 Results
3.4.1 Direct Tissue Profiling and
Direct tissue profiles were taken from untreated human skin using the Q-star 
pulsar-/ MALDI-TOF instrument, these displayed signals of good intensity 
(Figure 3.1) Peaks of higher abundance were selected as candidates for 
MS/MS.
I +TOF MS: 240 MCA scans from Sample 57 (PJHnegProfile a) of DataPJH hskindigest_ a=3.57031177631956190e-004, t0=5.60672130395284330e+001 Max. 5787.0 counts.
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Figure 3.1: MALDI-TOF-MS spectrum acquired from untreated human skin, 
over a m/z range of 800-3000, using the Qstar Pulsar-i
Selected precursor ions underwent collisionally induced dissociation (CID) to
provide product ion spectra, as shown in Figure 3.2. The MS/MS trace seen in
Figure 3.2 shows a good level of fragmentation, however, when examined more
carefully it is clear that there are multiple species present. The magnified area
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of the spectrum, shows product ions that are characteristic of a-CHCA matrix 
(190), phospholipids (184) and peptides (175). When examining the precursor 
ion and its isotopic pattern, there are no clear interferences that could be 
resolved through tightening the quadrupole and letting through fewer ions 
around the target m/z. This means that the interfering species are of isobaric 
mass and this leads to complex MS/MS that are not clear enough in order to 
obtain hits on database search engines, such as MASCOT (due to the presence 
of interfering product ions). This also makes it extremely problematic when 
processing these spectra through manual amino acid peak assignment. In 
order to clean up these MS/MS traces and obtain reliable, positive 
identifications it became evident that an extra method of separation is 
necessary for in-situ, “on-tissue” experiments. This is why the method of ion 
mobility separation (IMS) was introduced into this project.
Direct tissue profiles were taken from untreated human skin using the MALDI-
HDMS Synapt G2 instrument. These were then calibrated using the lockmass
facility in MassLynx and a sodiated polyethylene glycol (PEG) solution. An
example of the peptide mass fingerprints generated in this manner can be seen
in Figure 3.3A. The most abundant ions were then selected for MS/MS.
MS/MS spectra of peptides were generated through CID, with a transfer energy
ranging from 50-120 meV. Differing amounts of energy were acquired in order
to facilitate fragmentation of peptides of different size and conformation. Larger
peptides have been generally found to require the application of increased
energy to produce an MS/MS spectrum with adequate product ions for
database searching or DE-NOVO sequencing. Figure 3.3B shows the multiple
ions present at m/z 1118, further illustrating the necessity for IMS. Subsequent
to MS/MS acquisition, the data file was opened in Driftscope and the stream of
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product ions, along with the precursor ion of interest are separated, selected 
and exported, retaining the drift time. When the new chromatogram was 
opened in Masslynx it was possible to select the separated peak of interest and 
produce a cleaner, more specific product ion spectrum (Figure 3.3C), and 
potentially obtain a positive match through a MASCOT search of the UniProt 
database.
Lipid product ion 
(Phospholipid head group)
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Figure 3. 2: MALDI-MS product ion spectrum of a keratin 1 peptide (m/z 1118), 
with a magnified area showing peaks at m/z 175, 184 and 190, as well as a 
separate region displaying the precursor ion.
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Figure 3.3: Data acquired from the Waters Synapt G2, MALDI-HDMS system. 
(A) Displays a MALDI-MS trace, acquired in mobility mode from a cross section 
of untreated human skin, with a keratin 1 peptide (m/z 1118) in red. (B) displays 
a Driftscope plot, showing the multiple ions present at and surrounding m/z 
1118.5. (C) shows the product ion spectrum (related to that shown in Figure
3.2) generated after selecting and retaining the drift time of the ion of interest 
from the Driftscope plot, as well as the positive MASCOT ID assignment.
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Peptide Theoreticalm/z
Experimental
m/z Amino acid sequence
Post Translational 
Modification (PTM)
Cytokeratin 10 
(keratin 1) 1118.5086 1118.5112 HGNSHQGEPR N/A
Collagen alpha 1 
(III) - 1138.5601 G LAG PPG M PG PR
Oxidation on 
Proline (P) x 2
Collagen alpha 1 
(VI) 1258.7517 1258.7538 AGIEIFWVVGR N/A
Collagen alpha 1
(I) - 1105.5790 GVQGPPGPAGPR
Oxidation on 
Proline (P)
Collagen alpha 1
(I) 1297.6187 1297.6131 GESGPSGPAGPTGAR N/A
Collagen alpha 1
(I) - 1465.6912 GEPGPTGLPGPPGER
Oxidation on 
Proline (P) x 3
Serum Albumin 927.4954 927.4934 YLYEIAR N/A
Serum Albumin 940.4454 940.4483 DDNPNLPR N/A
Serum Albumin 960.5625 960.5454 FQNALLVR N/A
Serum Albumin 1311.7419 1311.7574 HPDYSWLLLR N/A
Serum Albumin 1511.8427 1511.8577 VPQVSTPTLVEVSR N/A
Serum Albumin 1623.7875 1623.7935 DVFLGMFLYEYAR N/A
Decorin 1163.5844 1163.5822 WEIQPSTFR N/A
Decor in 1248.7422 1248.7399 NLHALILVNNK N/A
Keratan sulphate 
proteoglycan 1060.5421 1060.5388 DFADIPNLR N/A
Keratin sulphate 
proteoglycan 
lumican
1024.5574 1024.5530 FNALQYLR N/A
Prolargin 1044.5221 1044.5170 WINLDNNR N/A
Table 3.1: Endogenous peptides identified in skin via MS/MS and a subsequent 
MASCOT search of the UniProt database.
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3.4.2 MALDI HDMS Imaging
MALDI-MS images were acquired using a MALDI-HDMS Synapt G2 instrument. 
Initial experiments were performed with a spatial resolution of 150 pm x 150 
pm. This was done in order to highlight which tryptic peptides could be imaged, 
and to make observations on any obvious distribution. The lower spatial 
resolution also allowed for reduced run times, enabling the setup of sequential 
images of multiple samples, as described in Chapter 5.
The images displayed in Figure 3.4 are of a number of identified and 
unidentified peptides (Table 3.1) that are thought to belong to proteins 
endogenous to the different layers of human skin. The image of the keratin 1 
peptide at m/z 1118.5 shows distribution throughout the region known to be the 
epidermis/stratum corneum. The other images appear to indicate the peptides 
of serum albumin, collagens and decorin etc. to be localised mostly within the 
epidermis and dermis (excluding the stratum corneum). There are also some 
subtle differences in the distribution within the epidermis/dermis (See Figures 
3.4B and 3.4G for comparison. Figure 3.4 shows that it has been possible to 
image multiple species, some of which that, as yet, remain unidentified.
In order to attempt to view more discreet distribution of tryptic peptides, further 
images were acquired at an improved spatial resolution of 30 pm x 30 pm. 
Figure 3.5 shows some examples of tryptic peptides imaged at this resolution. 
The images in Figure 3.5 show some enhancement of peptide distribution 
information. It was possible to successfully image a number of different m/z 
species, despite the reduced sensitivity associated with oversampling (the laser 
will fire on certain areas of tissue more than once, ablating sample and matrix),
122
in order to image at improved spatial resolutions (Jurchen et a i, 2006; Baluff et 
a i, 2011).
Figure 3.4: MALDI-MSI of peptides within untreated human skin, acquired at a 
spatial resolution of 150 pm x 150 pm on the MALDI HDMS SYNAPT G2™, and 
visualised in Biomap; (A) Keratin 1 (m/z 1118); (B) Serum Albumin (m/z 940); 
(C) Serum Albumin (m/z 927); (D) Prolargin (m/z 1044); (E) Decorin (m/z 1163); 
(F) Keratin sulphate proteoglycan lumican (m/z 1024); (G) Collagen alpha 1 (IV) 
(m/z 1258); (H) Keratan sulphate proteoglycan (m/z 1060). The plate layout 
can be seen in the centre, as exported from Waters high definition imaging 
(HDI) software, with the untreated skin image shown overlaying the optical 
image, and with a scan of the glass slide subsequent to acquisition. The stratum 
corneum is orientated at the top for all images.
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Figure 3.5: MALDI-MSI of untreated human skin, acquired at a spatial resolution 
of 30 pm x 30 pm on the MALDI HDMS SYNAPT G2™. The central image 
shows human skin sections mounted on a glass slide and coated with matrix. A 
keratin 1 peptide (m/z 1118), generated using the Waters HDI software is laid 
over the area from which it was acquired. The identity of the imaged peptides A, 
B, E-G (generated using Biomap), are as labelled on the individual images. 
Image C) displays an overlay of Keratin 1 peptide, m/z 1118 (green) and 
collagen alpha 1 (I) peptide, m/z 1105 (red). Image D) displays an overlay of 
Keratin 1 peptide, m/z 1118 (green) and Keratan sulphate proteoglycan, m/z 
1060 (red).
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The 30 x 30 |jm2 images show differentiation between the different layers of the 
skin and the different peptides are of varied localisation, as the 150 pm images 
also appear to suggest. It was not possible to produce all of the m/z species 
that were imaged at 150 pm spatial resolution at 30 pm. This may be due to a 
number of reasons that are further explained in section 3.5.2. The use of image 
overlays in Figure 3.5, C) and D), highlights the variation in localisation of 
different peptides. Image D) shows the keratan sulphate proteoglycan peptide is 
localised in the dermis and adipose tissue, at the bottom of the sample, as well 
as being co-localised with the keratin 1 peptide, that is only localised in the 
upper epidermis/stratum corneum. Image C) shows how the keratin 1 peptide 
and the collagen alpha 1 (I) peptide, are clearly not co-localised.
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3.4.2 Statistical Analysis
Replicate spectra were taken from the epidermis and dermis of 3 repeats of 
untreated human skin. In order to obtain these spectra, regions of interest were 
drawn over the epidermis and dermis in images generated from each replicate 
using Biomap MS imaging software. The resulting spectra were exported as 
text files. These spectral data were processed using SpecAlign™ software 
(Wong et a!., 2005). This software was used to generate an average spectrum 
and peaks in each of the spectra were subsequently aligned to the position of 
peaks in that average spectrum. All spectra were also normalised against the 
TIC.
This was implemented with the objective of normalising all data sets, so that the 
intensity of signals does not appear altered in different spectra due to interfering 
factors, such as increased matrix coverage, or instrumental variation. This is 
important so that significant increases in abundance of species within a 
particular sample/spectrum may be reported with confidence. The spectral 
alignment is also critical to compensate for any mass shift between image 
acquisitions.
Subsequent to the normalisation processes, the peptide spectra were imported
into mMass. Here, each spectrum was processed individually, deisotoped and
peak picked. With so many peptide and matrix signals present in the spectra,
the deisotoping step was crucial to remove as many isotopic species as
possible to reduce interference and the complexity of statistical plots. Peaks
were picked within the m/z range of 920-2500 and above the signal/noise
threshold of 3. The m/z range was chosen to exclude the majority of lipid
species that have been found to be persistent (even subsequent to tissue
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washing procedures) up to approximately, m/z 910 (the MS trace in Figure 4.2, 
section 4.4.1 may be used for reference).
3.4.2.1 Markerview Statistics
Initially, the processed data, consisting of 3 spectra taken from each layer in 4 
different images of untreated skin was put through PCA in the MarkerView™ 
software(ABSciex, Cheshire, UK) (Ivosev et a/., 2008). The results can be seen 
in Figure 3.6, where there are clear differences between data collected from the 
dermal and epidermal regions. Whilst the red and green markers (representing 
spectra from the epidermis and dermis, respectively), are not clustered tightly in 
their groups, they are clearly distinguishable from one another. The right side of 
the loading plot contains m/z values that are more prevalent in the dermis, and 
the left side, those in the epidermis. The m/z values that are the furthest from 
the centre of the plot and therefore, more characteristic of a specific area 
correlate with images of the peptides identified at these m/z. For example, 
/r?/z1105 and 1138, are positioned to the right hand side of the loading plot and 
are therefore shown as being more common to dermal regions and this is 
synonymous with the collagen peptides at these m/zvalues (as seen in Figures 
3.4 and 3.5). Similarly, m/z 1118 and 1119 (an isotopic peak of 1118) are seen 
to the left hand side of the loading plot, as would be expected of the keratin 
peptide present at this m/z, which is shown in Figures 3.4 and 3.5 to be 
specifically localised in the upper epidermis.
Further PCA-DA (supervised) analysis was then performed on the same set of 
data for comparison purposes. The epidermal and dermal spectral markers are 
clustered within the two groups but are more widely separated from each other. 
This is due to the supervised nature of the PCA-DA analysis, whereby the
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software is informed of which group each of the spectra is in, prior to analysis. 
In this case, the PCA-DA plots do not provide much more information than the 
initial PCA results. This is because the PCA results are already specific and 
interfering variables (such as instrument variability on different days of 
analysis), do not appear to have affected the plots to any great extent.
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3.4.2.2 MatLab Statistics
The same data sets used in section 3.4.2.1 were also input into MatLab (The 
MathWorks, Inc., 24 Prime Par Way, Natick, MA, USA) using the PLS_Toolbox 
(Eigenvector Research Inc., Wenatchee, USA), for further PCA analysis, to 
determine whether the results generated were similar to those obtained in 
MarkerView analyses. The loading plot (Figure 3.8) shows the same, clear 
differentiation between the markers representative of the epidermis (green) and 
dermis (red). Again, similarly to MarkerView results, the collagen signal, 
m/z1105 and keratin signal, m/z1118 are shown to be characteristic of the 
dermis and epidermis, respectively. The MatLab loading plot, however is not as 
easy to interpret as that generated in MarkerView, as more of the m/z species 
seem to be clustered in the centre of the plot.
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Figure 3.8: PCA score plot of mass spectra acquired from the epidermal and 
dermal regions within untreated human skin. The score plot shows the grouping 
of the spectra via commonalities in m/z ratios of peaks, red markers represent 
spectra taken from the epidermal region and green, from the dermal region.
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epidermis and dermis of untreated human skin. This loading plot directly correlates with the score plot in Figure 3.8.
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3.5 Discussion
3.5.1 On-Tissue Peptide Identification
It has been possible to identify a small number of peptides conclusively (Table 
3.1) using MALDI-IMS-MS/MS. The use of ion mobility separation (IMS) was 
crucial in making these identifications. As shown in Figure 3.2, Q-TOF analysis 
alone generates complex MS/MS comprised of product ions from matrix, lipid, 
and peptide species. This is also true of results obtained on the Synapt, 
MALDI-HDMS system, whilst in TOF-MS mode. However, when data is 
processed via Driftscope™, which allows display of the mobility separation 
dimension, subsequent to the use of IMS, a cleaner MS/MS trace can be 
obtained (Figure 3.3). This increases the likelihood of obtaining a match in a 
database. This is an improvement that has also been observed in other 
studies, such as that of Djidja et al. (2009) and Stauber et al. (2010). However, 
the level of separation achievable using MALDI-IMS MS/MS and traditional 
sample preparation for on-tissue analysis is still not ideal. Identification of 
peptides in-situ, on-tissue remains problematic. This is a time consuming 
process, particularly when considering the large amounts of data produced 
Bruand et al. (2011). Subsequent to the process of peptide identification 
attempted in this study it would be reasonable to suggest an alternative 
workflow.
Other studies, of biological nature have employed LC-MS/MS. The use of LC 
allows for further separation, with the sensitivity increase that can be gained 
with ESI (Kallenbach et al., 2009). In addition to the above advantages, (Hilton
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et al., 2010) have used nanoflow ESI in conjunction with travelling wave ion 
guide (TWIG) ion mobility to provide a further dimension of separation for 
isobaric species. Despite all of the advantages provided by LC-MS/MS for 
peptide/protein identification, it could still not replace MALDI-MS for studies 
such as this. One reason for this is the ability of MALDI-MSI to image biological 
molecules without the use of labelling (Heeren et al., 2009). Another would be 
the ability of MSI techniques to enable the generation of images of multiple 
species from one initial experiment (Thomas et al., 2011).
Taking into consideration all of the previous discussion, it would seem that an 
alternative workflow may be proposed, whereby LC-MS and MALDI-MS are 
used as complementary techniques. LC-MS/MS may be carried out on 
homogenised, digested tissue with the aim of identifying a large number of 
endogenous peptides. This would allow for the exclusion of any inherent 
peptides/proteins and highlight any that may be of interest to a particular 
biological pathway. Any ions of interest found in LC-MS may then be 
investigated in further MALDI-MS and MSI experiments, and also possibly 
searched for using statistical approaches (Bruand et al., 2011). This more 
targeted approach may significantly reduce the timescale of biomarker 
discovery studies, for example.
3.5.2 Peptide Imaging
MALDI images acquired at 150 pm (spatial resolution) correctly localise species
such as keratin, collagen, and decorin. The keratin peptides appear to be
localised within the epidermal/stratum corneum layers, which is in agreement
with reports from other researchers on human skin (Chamcheu et al., 2011, and
134
Nielsen et al., 2008). The images in Figure 3.4 highlight the difference in 
distribution of keratin and collagen peptides, in particular, the lack of collagen in 
the upper epidermis/stratum corneum. It is well known that collagen is 
generally present in the dermis (Nielson et al., 2008), and also in the case of 
collagen type IV, in the human epidermal basement membrane, around hair 
follicles and sweat glands (although this has not been observed in MALDI 
images) (Hasegawa et al., 2007). It may be possible to view the specific 
localisation of collagen IV in the areas discussed by Hasegawa et al., (2007) via 
the use of high resolution MALDI imaging in the future. The ability of MALDI- 
MSI to detect collagen in abundance may be of use in other areas of biomarker 
discovery, if not for observing irritant or sensitisation responses. For example, a 
recent study by Thrasivoulou et al. (2011) uses second harmonic imaging 
(SHG) to look at the relationship between collagen types I and III and cancerous 
skin tissue, also in ex-vivo human skin. It is possible that the reduction in 
collagen observed in the SHG study may also be observed using MALDI-MSI. 
Decorin, another protein shown in the images of Figure 3.4, is shown to be 
localised in the same area as the collagen peptides. This information is 
consistent with the collaborative role decorin has with collagen in skin 
homeostasis. Reed et al., (2003) describe how decorin binds collagen and 
mediates the process of fibrillogenesis, affecting the integrity of the fibers 
formed, and thus the integrity of skin.
The 30 x 30 pm images shown in Figure 3.5 show clear spatial differentiation 
between layers within each image and between the different peptides, much like 
the 150 x 150 pm images in figure 3.4. The high spatial resolution images show 
localisation of species in a more discreet manner, even showing the grain like
structure of the skin sections that are not smooth in texture.
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Possible disadvantages associated with the type of high spatial resolution 
imaging used in this study are; the decreased sensitivity from oversampling 
(Jurchen et al., 2006; Baluff et al., 2011) and peptide delocalisation across 
tissue sections (although little or no delocalisation can be seen in images in 
Figure 3.5). One solution to the issue of delocalisation that has been employed 
is the use of sublimation to apply the matrix to the tissue being analysed. This 
method has been used for “on tissue” lipid analysis (Murphy et al., 2011) and for 
the analysis of digested peptide solutions (Jaskolla et al., 2009). The only 
problem that may need to be overcome with “on tissue” analysis of tryptic 
peptides is the method of applying trypsin. If the trypsin is sprayed on and the 
matrix sublimed this may still improve the quality of high resolution images due 
to the smaller crystal size from sublimation (Jaskolla et al., 2009).
Although many improvements have been made to increase the spatial 
resolution capabilities of MALDI-MSI, this is still one of the main limitations of 
the technique. The lowest lateral resolution currently reported by Bouschen et 
al., (2010) was of 2 pm and was achieved using scanning microprobe MALDI- 
MS with enhanced and optimised matrix application.
3.5.3 Statistical Analysis
PCA results obtained in both of the software packages used i.e. MarkerView
and MatLab were found to be significant, as they are unsupervised, yet the two
regions of skin are clearly defined. This means that theoretically, other m/z
species that lie to the left of the loading plot are more commonly expressed in
the epidermis, and those to the right, the dermis. The presence of m/z signals
identified as keratin and collagen peptides in either the epidermis or basement
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membrane/dermis, is not only consistent with the images generated in this 
study (as shown in Figures 3.4 and 3.5), but also with information provided by 
other sources. Chamcheu et al., (2011), describe the role of keratin within 
disorders of human skin and refer to the presence of keratin within the 
epidermis, discussing how the mutation of keratin genes can lead to defects 
within the skin. Nielsen et al., (2008), discuss the absorption of UV by keratin in 
the epidermis increases with decreasing wavelengths of UV. Hasegawa et al., 
(2007), show the presence of collagen within the basement membranes of the 
skin, through the use of immunohistochemistry.
The MatLab loading plot, in Figure 3.9 is slightly different to that generated in 
MarkerView, as more of the m/z species seem to be clustered in the centre of 
the plot. This difference may simply be due to the different algorithms 
employed in the two software packages giving slightly different results. 
However, the same overall conclusion can be drawn from these statistical 
analyses, and this is that spectra taken from the different layers of skin can be 
easily differentiated, by the prevalence of certain peptide ions.
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3.6 Conclusion
It has been possible to conclusively identify a relatively small number of 
endogenous peptides/proteins using MALDI-IMS-MS/MS. The most abundant 
peptides found within the MALDI-MS of human skin samples were serum 
albumin and various types of collagen. It is proposed that this catalogue could 
be expanded upon, and over a shorter period of time with the alternative 
workflow suggested in Section 3.5.1, utilising LC-MS/MS.
MALDI-MS imaging experiments have proved successful in pinpointing the 
regions within which certain peptides are localised. However, the level of 
localisation information obtained does not alter significantly when the spatial 
resolution of images is improved from 150 x 150 pm2 to 30 x 30 pm2. This may 
be due to the potential ubiquitous nature of the peptides being imaged, or as a 
result of some molecular spreading within the tissue, during washing or matrix 
application steps.
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Chapter 4: Lipidomics
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4.1 Introduction
Lipids are essential components of biological systems and there is evidence for 
their involvement in disease pathogenesis. Holleran etal., (2006) discussed the 
role of Glucosylceramides (GlcCer) in the pathogenesis of Harlequin Ichthyosis, 
where the altered distribution of GlcCer leads to poor lamellar body formation, 
poor lipid barrier and stratum corneum formation. Many lipid classes are readily 
amenable to analysis by MALDI MS due to the presence of an easily ionisable 
head group, e.g., the phospholipid head group, often observed at m/z 184. The 
lipid classes that have been most thoroughly investigated using MALDI-MS 
include sphingolipids (SLs) and glycerophospholipids (GPLs) (Fuchs et al., 
2010). The phosphatidylcholine (PC) sub-class of GPLs has been indicated as 
playing a role in inflammatory processes. The species lysophosphatidylcholine 
(LPC) is formed where inflammation is induced, as demonstrated in cases of 
chemical exposure (Arnhold et al., 2002) and also as an aspect of disease 
pathogenesis (Wang et al., 2010). LPCs can be detected via MALDI-MS and 
are observed in mass spectra as an m/z shift of -52 from the original PC signal, 
which corresponds to the loss of one fatty acyl residue (Fuchs et al., 2009; 
2010). MALDI-MS imaging has been previously used to analyse skin biopsies 
taken from patients with Fabry's disease. In this case, as reported by Roy et al., 
(2006), a role for glycosphingolipids in disease pathogenesis was observed as 
they are found to accumulate in the skin of patients affected with the disease.
A large number of SLs and their associated metabolites are localised within the 
stratum corneum and epidermis. These lipid species are directly affected as a 
result of the proteome behaviour within skin (Doering et al., 1999) and as such, 
are also involved in disease pathogenesis (Fujiwaki et al., 2002). It has been
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established that sphingosine (Sph), sphingosine-1 -phosphate (S1P), ceramide 
(Cer) and ceramide-1-phosphate (C1P) have pivotal roles in apoptosis and 
other cell signalling pathways (Bartke et al., 2009). In particular, C1P and S1P 
have a role in the inflammation pathway and the arachidonic acid cascade, as 
reported by Chalfant (2005) and Pettus (2004). Due to this behaviour, along 
with the involvement that glucosylceramides and sphingomyelin (SM) have in 
atopic dermatitis (Melnik 1988; Di Nardo 1998; Imokawa 1999), there is much 
information to suggest that there may be a lipid response that is specific to 
sensitization.
Phosphocholine example: 
PC(18:0/16:1 (9Z))
Sphingolipid example:
Fatty acid example:
N-arachidonoyl leucine
Figure 4.1: Examples of lipid structures found in human skin, including a
phosphocholine, fatty acid and sphingolipid (as labelled). Structures were taken
from the Lipid Maps structural database
(http://www.lipidmaps.org/data/structure/).
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The aims of the work reported in this chapter were to:
Optimise the conditions for identification, detection and imaging of lipids within 
human skin, using MALDI-MS.
Identify endogenous lipids within normal human skin and confirm the 
localisation of these lipids using MALDI-MSI.
Perform multivariate statistical analysis using principal component analysis 
(PCA) and PCA- discriminant analysis (DA) on MALDI mass spectral repeats in 
an attempt to identify differences in expression of lipids within the epidermis, 
dermis and regions considered to be fat cells.
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4.2 Materials
Materials used in MALDI matrices include: alpha-cyano-4-hydrocinnamic acid 
(a-CHCA), aniline, acetonitrile (ACN), ethanol (EtOH), Lithium Chloride (LiCI) 
and trifluoroacetic acid (TFA), purchased from Sigma-Aldrich (Dorset, UK). In- 
house deionised water supplies were used in tissue washing procedures. Ex- 
vivo human skin was obtained from Ethical Tissue, Bradford University 
(licensed by the human tissue authority (HTA), and handled as described in 
chapter 2 (with materials stated in section 2.2). The carboxymethyl cellulose 
(CMC) used to embed the human skin samples was purchased from Sigma- 
Aldrich. The polylysine coated glass slides used were purchased from Thermo 
Scientific (Runcorn, Cheshire, UK).
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4.3 Methods
4.3.1 Human Skin Tissue Samples
The human skin was obtained from Ethical Tissue, Bradford, UK, licensed by 
the Human Tissue Authority (HTA) (REC 07/H1306/98). All human tissue was 
handled and stored in the appropriate ethical manner. Negative, untreated 
controls and controls, treated with only the acetone: olive oil (4:1) vehicle, were 
incubated alongside the chemically exposed skin samples (as described in 
Chapter 2, section 2.3.1). At the end of the incubation period, all samples were 
washed with PBS, before being placed into individual blister packs filled with 
CMC. The blister packs were then snap frozen on liquid nitrogen. An MTT 
assay was performed on replicate samples at the end of the experiment to 
determine tissue viability. The full MTT method is given in chapter 2, section
2.3.2.
4.3.2 Tissue preparation and matrix deposition.
Tissue sections (12 pm) were cut using a Leica 1850 UV cryostat (Leica, 
Microsystems, UK) and thaw mounted onto aluminium foil plates or polylysine 
coated glass slides. Sections were stored in a sealed container at -80°C prior 
to analysis. It was necessary to include a tissue washing step prior to analysis 
in order to remove excess salt and other impurities from the skin. The mounted 
sections were placed in deionised water for a period of 1 minute, subsequent to 
which, excess water was carefully tapped off and the sample left to dry. This
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wash step was repeated, and the sample allowed to dry before matrix 
application.
For imaging experiments, 5mg/mL a-CHCA was dissolved in a 70% EtOH and 
0.2% TFA solution with an equimolar amount of aniline being added prior to use 
(Armstrong et al., 2001; Lemaire et al., 2006). The matrix solution was then 
deposited onto the sample surface in a fine spray using the SunCollect™ (KR 
Analytical, Sandbach, UK) automated sprayer. The spraying protocol was 
altered from that of chapter 2, due to an upgrade in the automated sprayer. 10 
layers of matrix were applied using the continual spraying mode at medium 
speed, with the spraying needle at a distance of 2 cm from the tissue surface. 
The first two layers were sprayed at a flow rate of 10 pL/min, layers 3-8 at 15 
pL/min and the final 2 layers at 20 pL/min. For MS/MS experiments, 100 mM of 
LiCI (Jackson et al., 2005) was dissolved in 70% EtOH, 0.2% TFA, with a- 
CHCA being added to the solution to give a final concentration of 10mg/mL. 
Matrix was deposited onto the skin sections manually, with an air displacement 
pipette in 1 pL spots.
4.3.3 Direct On-tissue MALDI-MS/MS
MALDI-MS/MS spectra were acquired from the in situ skin sample surface using
a modified MALDI-Q-TOF, Q-Star Pulsar-/ ™(Applied Biosystems/MDS Sciex,
Concord Ontario, Canada). These modifications have been reported elsewhere
(Trim et al., 2010). Data was acquired in positive mode using an NdYV04 laser
(Elforlight "SPOT"), operated at 5 kHz repetition rate and 80% laser energy
(approximately 4.2 pJ). All MS/MS spectra were calibrated using a 100 mM
angiotensin II peptide standard (Sigma-Aldrich, St Louis, MO, USA) and its
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product ions. MS/MS spectra were processed using mMass, an open source 
mass spectrometry tool (Strohalm et al., 2008; 2010). Lipids were tentatively 
identified by accurate mass measurement against values in the mMass 
databases, the chemical structure of lipids (as listed on www.lipidmaps.org) that 
had been assigned with the greatest accuracy were then compared with product 
ions observed in individual MS/MS spectra to confirm identity.
4.3.4 MALDI-MS Imaging
MALDI-MS images were acquired using a modified MALDI-Q-TOF, Q-Star 
Pulsar-/ (Applied Biosystems/MDS Sciex, Concord Ontario, Canada). Data was 
acquired in positive mode using an NdYV04 laser (Elforlight), operated at 5 kHz 
repetition rate and 80% laser energy (approximately 4.2 pJ). All mass spectral 
data were recalibrated using lipid signals that had been previously identified via 
MS/MS. Data was acquired at a range of 400-1500 m/z and at a spatial 
resolution of 150 x 150 pm2.
30 pm MALDI images were also acquired using the Synapt G2, MALDI HDMS 
(Waters Corp., Manchester, UK) instrument. These were acquired at a lower 
laser power of 2.1 pJ (equivalent to 100 arbitrary units on the instrument), in 
order to obtain a smaller laser spot size. The high spatial resolution images 
were run on only a strip of cross-sections of human skin, due to time restrictions 
(i.e., for images such as those in Figure 4.6, an average run would take 
approximately 14-18 hours. This was performed on untreated skin samples. 
Data was acquired over an m/z range of 400-1000. Ion mobility settings, such 
as wave velocity were optimised prior to each acquisition.
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4.3.5 Data Processing
The majority of images were processed using Biomap Software 3.7.5.5 
(Novartis, Basel, Switzerland) (Stoeckli et al., 2002). Some images generated 
using the Synapt MALDI-HDMS (Waters Corp.) were also processed using the 
Waters High Definition Imaging (HDI) software package. These images were 
used to illustrate the areas from which the Biomap images were acquired.
Prior to statistical analysis, all spectral data were processed using SpecAlign™ 
software (Wong et al., 2005). This software was used to generate an average 
spectrum and peaks in all spectra being analysed were subsequently aligned to 
the position of peaks in that average spectrum, and all spectra were normalised 
against the TIC.
For Statistical analysis, PCA-DA was performed using MarkerView™ software 
(ABSciex, Cheshire, UK) (Ivosev et al., 2008). Subsequent to this MatLab, 
version 7.6.0 324 (R2008a) (The MathWorks, Inc., 24 Prime Park Way, Natick, 
MA, USA) was also used on the same data sets to provide further information. 
When using MatLab, the Eigenvector, PLS_Toolbox (Eigenvector Research 
Inc., Wenatchee, USA) was used. This software was used as an interface to 
input the data into MatLab and select the type of statistical analyses required, 
enabling the use of MatLab without the need for script writing.
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4.4 Results
4.4.1 On-Tissue Lipid Identification
4.4.1.1 High Mass Accuracy Measurements
Direct tissue profiling of human skin sections was implemented using a Waters 
Synapt MALDI-HDMS instrument. These profiles were performed in the high 
resolution mode of the instrument which employs the use of the dual reflectron. 
This allows for high mass accuracy measurements to be taken, with full-width 
half-height maximum (FWHM) resolution values of <40,000 being achieved and 
expected mass measurement accuracy to be <2 ppm. An example of the 
optimal peak shape that can be obtained is seen in the enlarged inset of Figure
4.2.
After acquisition, high mass accuracy measurements were imported into mMass 
for processing. Here, spectra were calibrated, smoothed and de-noised. From 
this point onward there were two separate routes that were taken to process the 
data. The compound search tool within mMass was used to analyse the 
spectra and tentatively identify lipid species, providing error margins. An 
alternative work flow involved the exportation of peak lists into the lipid maps 
(www.lipidmaps.org) MS analysis tool. This search tool provides a more 
detailed summary of possible lipid IDs, listing each of the potential isobaric 
species/isomers that may be present at a particular m/z. In addition to the error 
margins, and general lipid formula, this tool also suggests the mass of product 
ions that are specific to side chain structures, likely to be obtained via MS/MS, 
should certain lipids be present.
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Figure 4.2: High mass resolution, positive ion MALDI mass spectrum of normal 
human skin, using a-CHCA/ANI as a matrix, with an enlarged inset showing the 
peak resolution achieved (35,000- 40,000 FHWM) (Hart etal., 2011).
The lipid signal is most intense in the m/z region of 650-910. The majority of 
this signal has been identified (tentatively or otherwise) as belonging to PC or 
SM species, with glycerophosphonoethanolamines (PnE), 
glycerophosphoethanolamines (PE), glycerophosphates (PA) and 
triacylglycerols (TG), being found in smaller quantities. Much of the signal 
m/z<400 is thought to belong to a-CHCA matrix adducts, with the exception of 
the phospholipid head group at m/z 184. The lipid species tentatively identified 
to within 2 ppm can be seen in Table 4.1.
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4
4.4.1.2 MS/MS Lipid Analysis
Whilst it has been possible to identify some of the lipids within human skin, 
using high mass accuracy alone, there are a number of cases where an m/z 
signal could correspond to multiple, isobaric species. The extent of this can be 
seen in the Driftscope™ display of the ion mobility separation shown in Figure
4.3. The ions of lower drift time are more compact in their structure and/or of 
greater charge. There are clearly multiple ions at some m/z, most likely 
corresponding to a-CHCA matrix adducts or different classes of lipids.
In this event, the necessity for MS/MS data providing identification via 
fragmentation of the lipid structure, becomes clear. Some initial MS/MS 
experiments were largely unsuccessful, due to the lack of product ion 
information available. An example of this can be seen in Figure 4.4A, where the 
only fragments observed are the precursor ion and the abundant phospholipid 
head group (m/z 184). This information alone is not sufficient to identify the 
species in question as it only suggests that a phospholipid is present at this m/z.
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This issue has been extensively reported in the literature and in order to 
improve the fragmentation of lipid precursor ions, salts, such as lithium chloride 
(LiCI) have previously been added to standard matrices (as in the case of 
Jackson et al., 2005). Figure 4.4B the MS/MS spectrum obtained from the 
same lipid species following addition of 100mM LiCI to the matrix solution 
clearly shows an increase in the number of product ions detected. This 
indicates that [M+Li]+ precursor ions are more easily fragmented than [M+H]+ 
ions, thus providing greater structural detail required for identification. For the 
spectrum in Figure 4.4B the precursor ion selected was m/z 709.5 (the lithium 
adduct of the [M+FI]+ ion at m/z 703.5, as observed in Figure 4.4). The product 
ions belonging to the side chains of the lipid can be seen and identify the 
species as being SM (18:1/16:0), from the phospholipid sub class of SM, (also 
known as ceramide phosphocholine). In this case the m/z 264 product ion, 
characteristic of an 18:1 side chain, was crucial for identification as it allowed 
differentiation from other, isobaric SM species (SM (18:0/16:1) and SM 
(17:1/17:0)). Structural information was obtained via the “Lipid Maps” structural 
database (Sud et al., 2006). Where MS/MS has been successful, lipids have 
been identified through the structural assignment of the product ion spectrum, 
where the signals seen are specific enough to determine the length of side 
chains, but not the bond positioning within each side chain (Hart etal., 2011).
Lipids identified using the lithiated MS/MS method are listed in Table 4.2. Some 
of the error margins are much higher than for the high mass accuracy 
measurements. This meant that they could not have been identified through 
RMM alone, making the MS/MS analyses crucial.
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Phospholipid head 
group (m/z 184)
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Figure 4.4: (A) Positive ion MALDI product ion mass spectrum of the m/z 
species 703, identified to be SM(18:1/16:0) [M+H]+, (B) Positive ion MALDI 
product ion mass spectrum of the lithium adduct of SM(18:1/16:0) ([M+Li]+) m/z 
709.5, displaying the corresponding molecular structure (Hart et al., 2011).
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4.4.2 Lipid Imaging
4.4.2.1 MALDI-MSI Using the Q-Star Pulsar-i
MALDI-MS images were acquired directly from tissue at a spatial resolution of 
150 x 150pm2. The lipid species in the images in Figure 4.5 are predominantly 
localised in the epidermis with some small signals arising from fat cells located 
in the hypodermis also being visible. Spectra from the epidermal and dermal 
regions of the skin (Figure 4.5) were generated through Biomap from specific 
regions of an image, known to correspond to the epidermis and dermis, based 
upon histology of skin sections in H&E staining. There are clear differences 
between the two layers, with the m/z region where the majority of SM and PC 
lipids have been identified being of greater intensity in the epidermis. The lower 
m/z area in the spectra is more intense in the dermis and whilst some of the 
peaks seem to belong to possible lipid species, there does appear to be greater 
matrix interference at the lower m/z area, as might be expected. Figure 4.5 also 
shows an image overlay of the lipid species at m/z 760.58 (PC 34:1) and m/z 
907.77 (TG 54:3). It is clear that PC 34:1 has been detected in the epidermis, 
as with most of the lipids identified in experiments. When comparing the 
localisation of TG 54:3 to the epidermal lipid and the H&E optical image in figure 
4, it would appear that the TG 54:3 lipid is predominantly located in the stratum 
corneum.
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CerP (18:1/18:1) [M +Na]' m /z666.48 PC(O-14:0/18:1) [M+Na]* m /z 718.57 
Overlaid with:
CerP (18:1/18:1) [M +Na]' m /z 666.48
PC(O-14:0/18:1) [M +N a]'m /z718.57
dermis
captured at 
20
magnification
PC 34:1 [M + H ]'m /z  760.58 PC 34:1 [M +H]' m /z 760.58 
Overlaid with:
TG 54:3 [M+Na]* m /z 907.77
TG 54:3 [M +Na]' m /z 907.77
Figure 4.5: MALDI-MS images and spectra from normal human skin, acquired 
at spatial resolution of 150 pm (lipid identity is as labelled on individual images, 
A-F). An image overlay of the lipid species at m/z 760.58 (PC 34:1), (in red), 
and m/z 907.77 (TG 54:3), (in green) are shown in image B; and an overlay of 
the lipid species PC(0-14:0/18:1) [M+Na]+ m/z 718.57 (in red), and 
CerP(18:1/18:1) [M+Na]+ m/z666.48 (in green) are shown in image E. H&E 
stained sections of normal human skin, captured at x20 and x300 magnification 
showing the stratum corneum, epidermis and dermis are displayed centrally 
(Hart et al., 2011).
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4.4.2.1 MALDI-MSI Using the Synapt G2
Further MALDI images were acquired at a spatial resolution of 30 x 30 pm2. 
Figure 4.6 shows the area within the skin cross section, from which the data 
was acquired and images of lipids that were obtained. As was the case with the 
150 pm2 images, these 30 pm2 images show the position of the identified lipids 
to be predominantly present in the epidermal area and fat cells located in the 
hypodermis.
m /z6 6 6 .4 8 , CerP (18:1 /18:1) I  I  m /z939.78, Unknown
m/z 666.48 overlay ing m /z 939.78
m/z 784.67, Unknown
Figure 4.6: MALDI-MS images and spectra from normal human skin, acquired 
at spatial resolution of 30 pm (lipid identity is as labelled on individual images), 
including an image overlay of the lipid species CerP(18:1/18:1) [M+Na]+ at m/z 
666.48 (in green) with an unknown lipid at m/z 939.78 (in red). An optical image 
of the skin sample, showing the area of acquisition is also included. See Figure 
4.4 for the size scaling of skin sections, as demonstrated through the use of an 
H&E stained, consecutive skin section.
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The images in Figure 4.5 and 4.6 show how it is possible to use specific lipids 
as markers for different layers of skin. This is a theory that is investigated 
further through statistical analysis, as reported in section 4.4.3. Statistical 
Analysis.
Spectra were taken in triplicate from the epidermis, dermis and fat cells (thought 
to be present in the hypodermis, as seen in images in Figures 4.5 and 4.6) 3 
repeats of untreated human skin (giving 9 spectra in total). In order to obtain 
these spectra, regions of interest were drawn in triplicate within the epidermis, 
dermis and fat cells in each replicate image, generated in Biomap, with the 
resulting spectra being exported as text files. These spectral data were 
processed using SpecAlign™ software (Wong et al., 2005). This software was 
used to generate an average spectrum and peaks in each of the spectra were 
subsequently aligned to the position of peaks in that average spectrum. All 
spectra were normalised against the TIC.
Similarly to data analysed in Chapter 3, this was implemented with the objective 
of normalising all data sets, so that the intensity of signals does not appear 
altered in different spectra due to interfering factors, such as increased matrix 
coverage, or instrumental variation. This is important so that significant 
increases in abundance of a species within a particular sample/spectrum may 
be reported with confidence. The spectral alignment is also critical to 
compensate for any mass shift between image acquisitions.
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4.4.3.1 Principal Component Analysis (PCA)
The results of the Markerview PCA are not grouped according to the skin 
region, instead, the data has grouped according to the date of acquisition 
(Figure 4.7). The results from the MatLab PCA in Figure 4.8 show some 
grouping of spectra taken from fat cells, in the top right quadrant of the score 
plot. When comparing this with the loading plot, it is reasonable to deduce that 
this is related to the increase in m/z 760 in these spectra. This finding would be 
consistent with images in Figure 4.6, showing m/z 760 to be localised not only 
in the epidermis, but also, abundantly in the subcutaneous fat cells. The 
markers corresponding to epidermal spectra are grouped in the lower half of the 
score plot, consistent with the SM and PC m/z species that are in this region of 
the loading plot. Again, this correlates with images in Figure 4.6 and those in 
Hart etal. (2011).
Despite some grouping according to different skin regions, it is clear that the 
variability between acquisitions has had a greater impact upon the statistical 
analysis carried out here, as some spectra appear as though they may be 
grouping based upon the date of acquisition. Suggestions as to why this is 
occurring and possible solutions can be found in Section 4.5.3.
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4.4.3.1 Principal Component Analysis-Discriminant Analysis
(PCA-DA)
As in previous chapters, PCA-DA was implemented in addition to unsupervised 
PCA, on the same spectral text files. It was hoped that the use of a supervised 
methodology i.e one where the grouping had been defined would result in the, 
variation between acquisitions having less of an impact on the results. 
Examining the scores and loading plots in Figure 4.9, from the supervised 
statistical analysis it is clear which m/z species are most abundant in each of 
the regions of skin. For example, the ceramide species at m/z 666, which is 
known to be localised only in the stratum corneum and upper epidermis (Figure 
4.6), influences the positioning of the epidermis markers in the score plot. An 
example of an m/z species which influences the position of fat cell markers is 
m/z 760 (in the top right quadrant), and for dermal markers, m/z 939 (bottom left 
quadrant). The localisation of these m/z species to their respective regions is 
confirmed in images in Figures 4.5 and 4.6.
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4.5 Discussion
4.5. 1 On-Tissue Lipid Identification
Initial tentative identification of the lipid species in ex vivo human skin, detected 
by accurate mass measurement highlighted some of the issues with this 
approach; some of the signals only matched lipids in the database with poor 
mass accuracy (probably due to overlapping species, even with 35,000-40,000 
FHWM), but were still identified via MS/MS (as in Table 4.2). Due to the 
similarity in mass of many of the SM and PC lipids this is likely to be an issue 
with a large number of the species being investigated. This is an issue that may 
be partially resolved via the use of high mass resolution instruments such as an 
FT-ICR, Orbitrap and those possessing a dual reflectron mass analyser (such 
as the MALDI HDMS SYNAPT G2-HDMS). However, a method that would 
allow for the identification of an even larger number of lipid species would 
include the incorporation of ion mobility separation, aiding in the determination 
of isobaric lipid species. MALDI ion mobility (IM) MS has proved to be 
extremely efficient in separating phospholipids from other biomolecules, such as 
peptides, as well as from other phospholipids of the same or similar 
monoisotopic mass (Jackson et al., 2007; Calvano etal., 2009).
The majority of the lipids identified in this study are SM and PC species in the 
m/z range 650-800. This is a common occurrence when using a-CHCA as a 
matrix, in tissues such as liver and brain, as they are highly abundant and easily 
ionised (Shrivas et al., 2010). Theoretically it should be possible to detect other 
lipid species within the samples analysed in this study. One possible
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explanation for the reduced detection of lipids that has been posed in a previous 
study is that the SM and PC species that are so abundant and readily ionisable 
in skin, are suppressing other signals (Petkovic et al., 2001).
There are a number of possible solutions to this issue. One potentially 
straightforward way of preferentially ionising lipid species other than PC and SM 
would be to use different MALDI matrices. DHB is often used in the analysis of 
lipids within tissue (Murphy et al., 2008). Although many PC species are still 
detected when ionised positively, if DHB is employed as a matrix for negative 
mode MALDI-MS, a variety of other species have been detected including 
sulfatides as reported by Chen et al., (2008). Another method that has been 
previously employed in order to enhance the signal of lipid species that may be 
suppressed by the abundant PCs is discussed by Johanson et al., (2007). Here 
the MALDI-MS was performed on homogenised and fractionated samples. 
Lipids underwent cationic extraction whilst in a chloroform-methanol solution, 
allowing for the improved detection and identification of phosphoinositides 
(Ptdlns). For the detection of fatty acids, it may be possible to analyse specific 
areas of skin, such as the subcutaneous layer and/or analyse only a lower mass 
range (e.g., 200-600 m/z), thus excluding the majority of the PC and SM 
species that are of higher m/z.
4.5.2 Lipid Imaging
It has been possible to produce MALDI images of lipid species in skin of high
spatial resolution. As can be seen in Figure 4.5, there appears to be little or no
evidence of diffusion of lipid species, when imaged at a spatial resolution of 150
x 150 pm2. This still appears to be the case in the images acquired at a spatial
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resolution of 30 x 30 pm2 (Figure 4.6), lipid species are still associated with 
specific skin layers. This is pleasing since delocalisation of species is something 
that can occur when tissue washing is incorporated into a MALDI-MSI protocol. 
However the simple water wash reported here, does not appear to cause this 
effect. The images in Figure 4.5 and 4.6 provide valuable structural and 
localisation information. When compared to H&E stained sections, 
determination of lipid localisation is possible in the 150 pm images and further 
confirmation of their distribution is seen in the 30 pm images. The image 
overlay of the lipid species at m/z 760.58 (PC 34:1) and m/z 907.77 (TG 54:3) in 
Figure 4.5, shows the difference in distribution of the two lipids. This is 
significant as it shows that using this MALDI-MSI method it has been possible to 
define the distribution of lipids identified to specific regions of human skin, even 
with acquisitions at lower spatial resolution. The image overlay in Figure 4.6 
shows how, with spatial resolution of 30 pm, it is possible to determine lipid 
distribution to discreet locations. In this case the enhanced spatial resolution 
makes it possible to see that whilst the lipid species CerP (d18:1/18:1) and PC 
(0-14:0/18:1) are co-localised in the epidermis, PC (0-14:0/18:1) has been 
detected in areas thought to correspond to fat cells in the hypodermis. This 
overlay also indicates that PC (0-14:0/18:1) is more widespread in the 
epidermis than CerP (d18:1/18:1). As mentioned previously this cannot be 
observed in the same overlay at 150 pm, as valuable structural information is 
missing, thus indicating the requirement for images of lower spatial resolution in 
order to visualise distribution within such small regions of human skin.
The localisation of the CerP (d18:1/18:1) lipid within the upper
epidermis/stratum corneum is consistent with the review findings of Holleran et
al., (2006). This review describes how ceramides are largely located in the
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extracellular domains of the stratum cornuem. This review also confirms the 
high abundance of SM species within areas of the epidermis. Furthermore, it 
also explains that SM is converted to Ceramide by sphingomyelinase, as part of 
epidermal barrier homeostasis, thus explaining their co-localisation in the 
stratum cornuem/epidermis.
As mentioned previously, images generated in Biomap were all normalised 
through the division of the analyte image by that of a confirmed matrix ion, (m/z 
417 in this case). The intensity of the m/z species in the images is then stated 
as a ratio of Analyte: matrix. Images were normalised against the matrix so that 
any heterogeneity in matrix coverage did not affect the presentation of an 
analyte ion in different areas of the tissue image. This method is also 
advantageous as the majority of background noise is removed from the images 
along with the matrix. Further background noise removal and baseline 
correction is applied when generating images, as part of a standard procedure. 
In other studies, images have been normalised to the TIC (Sugiura et al., 2009). 
This is proposed to improve the quantification of analytes within the image, as 
well as to compensate for non-homogenous matrix crystallization. Whilst this 
may be a good method for normalization of intensity in non-diverse tissue types, 
it is less suitable for tissues where the abundance of analyte ions differs greatly 
throughout, as it could give a false representation of analyte ion distribution 
(Norris et al., 2007). It is for this reason that the images generated in this study 
were normalised against a known matrix ion, thus preserving the distribution 
information in the different layers of the skin.
It is however, worth noting that there are still issues with normalisation against 
matrix peaks. An example of this is illustrated in Figure 4.10. For images of
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poorer spatial resolution and multiple sample Biomap images, the spatial 
distribution of lipids does not alter between pre- and post-normalisation. It may 
be that the difference in appearance between the images (for example, Figure 
4.10 (A) and (B)) can be explained through the removal of noise. However, as 
can be seen in the matrix image (Figure 4.10 (C)), there are areas in the image 
that do not appear to have any signal. This may be due to differences in 
interaction of the matrix with the different histological layers of the skin. 
Therefore, in certain regions of any image, when being normalised, the analyte 
ion count would be divided by 0, thus not necessarily giving a true 
representation of matrix coverage. This highlights a need for some form of 
normalisation that takes into account the difference in histology of complex 
tissue samples. Some studies have employed the use of internal standards that 
are applied to tissue samples homogenously and use these for the basis of 
normalisation. It is proposed that an internal standard, optimised for the specific 
tissue being analysed may be a more suitable tool for normalisation than the 
matrix, in certain circumstances. One recent paper by Fonville et al., (2012), 
discusses this issue in further depth, comparing different methods of 
normalising MALDI MSI, such as normalisation against matrix TIC, against a 
species endogenous to the tissue, against the TIC of all data and to the TIC of a 
reference molecule/external standard.
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m/z 939.78, Unknown
m/z 417, a-CHCA matrix
m/z 760.58, PC 34:1
D
m/z 939.78, Unknown
Figure 4.10: MALDI-MS images of a cross section of untreated human skin 
(with the stratum corneum at the top of each image), acquired at a spatial 
resolution of 30 pm x 30 pm. Images labelled B (m/z 760) and E (m/z 939) have 
been normalised against the matrix peak, m/z 417 (C), and the images labelled 
A (m/z 760) and D (m/z 939) have not been normalised.
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4.5.3 Statistical Analysis
PCA results from the MarkerView (ABSciex, Cheshire, UK) software, do not 
show any significant difference between the spectra taken from the epidermis, 
dermis and fat cells. Instead, the markers representing the individual spectra 
appear to group according to the time at which they were acquired. This clearly 
shows that there are a number of variables affecting analyses run on different 
days. These could be attributable to instrumental variability (i.e. calibration, 
temperature etc.), or possibly also due to deviation in sample preparation (the 
trypsin/matrix coating, or variations in the tissue sections themselves. PCA-DA 
was investigated as a way to compensate for day to day variations in data. This 
use of discriminant analysis makes it possible to inform the software of the 
grouping of the samples that are to be compared (in this case, the 3 different 
layers of untreated human skin).
Through the use of discriminant analysis it was possible to see significant 
differences between the skin layers, both in the score and loading plots. 
Spectra taken from areas believed to be fat cells appear to have similarities to 
both the dermis and epidermis. However, when examining the loading plot, it 
appears that the biggest difference in the fat cells is attributable to m/z 760 
(identified as PC 34:1), which is of greater abundance in these regions. The 
epidermis is shown to have a higher abundance of previously identified SM and 
PC species (e.g. m/z 725, SM(34:1); m/z 666, CerP(18:1/18:1)), as can be 
confirmed in the images of Figures 4.4 and 4.6 The m/z species that are less 
prevalent in epidermal, but more so in dermal spectra are those that are of 
lower general abundance compared to SM and PC species (see spectrum in 
Figure 4.2). Some of these species may be a-CHCA adducts. However, m/z
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577.48, for example, may be attributable to one of the fatty acyl glycosides that 
are present in this mass region (as identified in the Lipid Maps structural 
database), and others, such as 939.71, remain unknown but can clearly be 
seen to be specific to dermal regions in MALDI-MSI (Figures 4.4 and 4.6).
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4.6 Conclusion
It has been possible to identify endogenous lipids within ex-vivo human skin 
tentatively, through high mass accuracy measurements. Ion mobility separation 
has facilitated MS/MS identification of species where multiple, isobaric lipids are 
present. The addition of LiCI to matrices improved the efficiency of MSMS 
analyses (an increase in the number of product ions was observed). This 
allows for structural characterisation in addition to RMM.
The majority of species identified using a-CHCA/ANI matrix were sphingolipids 
and glycerophospholipids, particularly in the m/z region of 490-800. In order to 
increase the range of lipids identified it would be necessary to alter sample 
preparation, e.g. washing to remove the most abundant PC and SM species 
and/or employ the use of alternative matrices in positive and negative ionisation 
modes.
It has been possible to image the aforementioned lipid species at spatial 
resolutions of 150 and 30 pm. Through these MALDI images it has been 
possible to visualise the distribution of lipids within the different layers of human 
skin.
Statistical analyses have shown some differentiation between spectra acquired 
from different regions of a skin cross section, also indicating the possibility of 
using specific lipids as markers for particular layers of skin (e.g., epidermis and 
dermis).
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Chapter 5:
Sensitization and Irritation 
Responses in Human Skin
185
5.1 Introduction
As discussed in chapter one, animal testing in the cosmetic industry is to be 
banned in the near future. Therefore it is crucial that other methods of 
investigating the potential toxicological effects of chemicals and processed 
formulations are developed. The majority of the in-vitro methods currently being 
investigated for the testing of chemical sensitizers involve the use of cell based 
assays. Some of these include the human cell line activation test (h-CLAT) 
(Sakaguchi et al., 2010), the direct peptide reactivity assay (DPRA) (Gerberick 
et al., 2009) and the myeloid U937 skin sensitization test (MUSST) (Ade et al.,
2006); all of which are described in Chapter 1, section 1.2.1.2.
There is currently, a validated in-vitro test for irritation, employing the use of a 
reconstructed, synthetic skin model; EpiDerm™ (Kidd etal., 2007), as described 
in Chapter 1, section 1.2.1.2. However, sensitization tests involving the use of 
full skin models are still very much in the developmental stages (Aeby et al., 
2010). Aeby et al., (2010) discuss the on-going development of a synthetic 
skin model composed of human dendritic cell (DC)-like cells, primary human 
keratinocytes, and dermal fibroblasts. This is crucial as the current validated 
skin model, EpiDerm™, does not contain the viable dendritic cells that are 
known to play a pivotal role in the process of skin sensitization (Ryan et al.,
2007). All experiments in this project were performed on ex-vivo human skin, in 
the absence of an alternative, and with the aim of transferring any developed 
methods at such a time that one becomes available.
MALDI-MS has been used in similar areas of analysis previously, shown in the
studies of Aleksic et al., (2007, 2008). Here, MALDI-MS was used to analyse
model proteins, such as: cytokeratin 14, cofilin and human serum albumin
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(HSA), which had previously been exposed to DNCB. The DNCB was found to 
modify the structure of the model proteins, and valuable insight into the 
behaviour of DNCB as a sensitizing agent was provided.
The main aim of the work reported in this chapter was to identify any differences 
in the biology of the skin as a result of its exposure to chemical irritants and 
sensitizers, using MALDI-MS and MSI.
MALDI-MS imaging was performed on ex-vivo human skin treated with 
chemical sensitizers, an irritant, vehicle controls and untreated (negative) 
controls. Acquisitions were sequential and images were generated for all 
sample sections in one experiment, in order to allow for any change in 
regulation of m/z species to be identified.
MALDI-MS spectra were taken from the epidermal region of each of the sample 
types and examined by multivariate statistical analysis in an attempt to highlight 
any species of interest and visualise similarities between sample classes. The 
techniques used included: Principal component analysis (PCA), PCA- 
discriminant analysis (DA) and partial least squares discriminant analysis (PLS- 
DA).
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5.2 Materials
All materials used in MALDI matrices including: a-CHCA, aniline, ACN, EtOH, 
Lithium Chloride (LiCI) and TFA, were purchased from Sigma-Aldrich (Dorset, 
UK). The materials used in the treatment of human skin were also purchased 
from Sigma-Aldrich (Dorset, UK), these included the chemical irritants and 
sensitizers: SLS; glycerol; DNCB; cinnamaldehyde; hydroquinone;
sulfamethoxazole, and CMC. The isopropanol and formazan solution used in 
the MTT assay were also obtained from Sigma-Aldrich (Dorset, UK). 
Dulbecco’s phosphate buffered saline (PBS) and Dulbecco’s modification of 
Eagle's medium (DMEM), used during the chemical treatment of human skin 
were purchased from Invitrogen (Paisley, UK).
188
5.3 Methods
5.3.1 Human Skin Tissue Samples
The human skin was obtained from Ethical Tissue, Bradford, UK, licensed by 
the Human Tissue Authority (HTA) (REC 07/H1306/98). All human tissue was 
handled and stored in the appropriate ethical manner. The skin sections were 
treated with the chemical irritants; sodium lauryl sulphate (SLS) and glycerol 
and sensitizers; cinnamaldehyde, hydroquinone, sulfamethoxazole and 2,4- 
dinitrol-chlorobenzene (DNCB), dissolved in a 4:1 acetone: olive oil vehicle. 
Subsequent to treatment, samples were incubated at 37°C, 5%C02/ 95% air for 
either 6  or 12 hours in DMEM. Samples were washed in Dulbecco's PBS before 
being frozen. Negative, untreated controls and controls treated with only the 
acetone: olive oil (4:1) vehicle were also incubated alongside the exposed 
samples. At the end of the incubation period, all samples were washed with 
PBS, before being placed into individual blister packs filled with CMC. The 
blister packs were then snap frozen on liquid nitrogen. An MTT assay was 
performed on replicate samples at the end of the experiment to determine 
tissue viability (the full MTT methodology is given in Chapter 2 Section 2.3.2).
5.3.2 Tissue preparation and matrix deposition.
12pm frozen tissue sections were cut using a cryostat 1850 UV, Leica 
Microsystems, UK) and thaw mounted onto aluminium foil plates or polylysine 
coated glass slides. Sections were stored in a sealed container at -80°C prior 
to analysis.
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5.3.2.1 Proteomic Protocol
The mounted tissue sections were washed in 70% ethanol for one minute, 
followed by one minute in 90% ethanol. Both ethanol solutions were stored at - 
20°C prior to use. Slides were then washed with chloroform for 5 seconds by 
submersion to remove lipids, which may interfere with peptide detection due to 
similar mass values.
Porcine derived trypsin (Promega) was dissolved in 50mM NH4HCO3 
(approximately pH8 ) to give a 20 pg/mL solution. 1 pL of the detergent, 10 mM 
Octo-a1 p glucoside (Sigma-Aldrich) was then added to the trypsin solution to 
assist solubilisation of proteins. The trypsin was applied to the skin section 
using the SunCollect™ (KR Analytical, Sandbach, UK) automated sprayer. Five 
layers of matrix were applied at the following flow rates: 1.5 pL/min, 2.5 pL/min, 
and a final three layers of 3.5 pL/min. The instrument capillaries were flushed 
with deionised water before the spraying of trypsin and then subsequently with 
100% acetonitrile (Sigma-Aldrich). The sections were then placed in a chamber 
(humidified with 50:50 methanol: water) and left to incubate for a minimum 2 
hour period at 37°C, 5% C 02/ 95% air.
1 mL of 5 mg/mL a-CHCA in 50:50 acetonitrile: water, 0.1% TFA, 2.4 pL aniline 
(Sigma-Aldrich) was prepared as a matrix solution. A sonication step was 
performed after the addition of acetonitrile and then again after the addition of 
aniline. The matrix was then sprayed onto the tissue sections using the same 
method as for the application of trypsin. The Suncollect™ instrument was 
flushed with 1 0 0 % acetonitrile after completion of the run.
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5.3.2.2 Li pi domic Protocol
The mounted sections were placed in deionised water for a period of 1 minute, 
subsequent to which, excess water was carefully tapped off and the sample left 
to air dry. This wash step was repeated, and the sample allowed to dry before 
the matrix application. The aim of this water washing step was to remove salts 
and impurities present in the sample.
For imaging experiments, 5mg/mL a-CHCA was dissolved in a 70% EtOH and 
0.2% TFA solution with an equimolar amount of aniline being added prior to use 
(Armstrong et al., 2001; Lemaire et a l 2006). The matrix solution was then 
deposited onto the sample surface in a fine spray using the SunCollect™ (KR 
Analytical, Sandbach, UK) automated sprayer. The spraying protocol is altered 
from that described in chapter 2 , due to an upgrade in the automated sprayer. 
1 0  layers of matrix were applied using the continual spraying mode at medium 
speed, with the spraying needle at a distance of 2  cm from the tissue surface. 
The first two layers were sprayed at a flow rate of 10 pL/min, layers 3-8 at 15 
pL/min and the final 2 layers at a rate of 20 pL/min.
5.3.4 MALDI-MS Imaging
MALDI-MS images were acquired from the in situ skin sample surface using a
MALDI HDMS SYNAPT G2™ system (Waters Corporation, Manchester, UK).
Images of 150 pm spatial resolution were acquired sequentially at laser power
of approximately 3 pJ (equivalent to 150 arbitrary units on the instrument).
Multiple images were run under one project name in Masslynx, allowing for
them to be converted for viewing in Biomap (Novartis, Basel, Switzerland),
either individually or together (showing multiple sections in one Biomap image).
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Data was acquired over an m/z range of 700-2500 for peptides and 300-1000 
for lipids.
5.3.5 Data Processing
The majority of images were processed using Biomap Software 3.7.5.5 
(Novartis, Basel, Switzerland) (Stoeckli et al., 2002). Some images generated 
using the Synapt MALDI-HDMS (Waters Corp.) were also processed using the 
Waters High Definition Imaging (HDI) software package.
Prior to statistical analysis, all spectral data were processed using SpecAlign™ 
software (Wong et al., 2005). This software was used to generate an average 
spectrum and peaks in all spectra being analysed were subsequently aligned to 
the position of peaks in that average spectrum, and all spectra were normalised 
against the TIC. Peptide spectra for statistical analysis were also processed 
using mMass, an open source mass spectrometry tool (Strohalm et al., 2008, 
2010). mMass was used to deisotope and peak pick the mass spectra 
generated in peptide analysis.
For statistical analysis, PCA-DA was performed using MarkerView™ software 
(ABSciex, Cheshire, UK) (Ivosev et al., 2008). Subsequent to this MatLab, 
version 7.6.0 324 (R2008a) (The MathWorks, Inc., 24 Prime Par Way, Natick, 
MA, USA) was also used on the same data sets to provide further information.
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5.4 Results
5.4.1 Peptide Imaging
Using images acquired using a MALDI HDMS SYNAPT G2™ system (Waters 
Corporation, Manchester, UK), at a spatial resolution of 150 x 150 pm2, it has 
been possible to analyse the expression and localisation of peptides within all of 
the treated and control samples at once. Figure 5.1 illustrates each of the 
differently treated skin samples sectioned at 1 2  pm and thaw-mounted onto the 
same glass slide. Images of the individual sections were acquired 
consecutively, after being spray coated with a homogenous layer of matrix. 
After acquisition the raw data files, all of the images were converted using 
Waters imaging converter software, so that they could all be viewed in one 
Biomap image. This was a useful function when looking for changes in 
regulation of species between skin that had been treated with irritants, 
sensitizers, the vehicle, or left untreated.
Figure 5.1: An optical image displaying the sprayed sample sections, as
analysed on a single glass slide. Sample sections are depicted in rectangular 
boxes for clarity.
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The Image in Figure 5.2, shows up-regulation of the m/z species 1183.5and 
1369.7, within the sulfamethoxazole and DNCB treated skin sections, 
particularly within the epidermal region.
6mm
Figure 5.2: A MALDI image of a peptide species present at m/z 1183.5(A) and 
m/z 1369.7 (B).The image shows difference in levels of expression between: (i) 
human skin that was treated with the acetone: olive oil vehicle, (ii) SLS treated 
(iii) untreated, (iv) treated with glycerol, (v) DNCB treated and (vi) 
sulfamethoxazole treated.
194
5.4.2 Lipid Imaging
5.4.2.1 MALDI-MSI Using the Synapt G2
MALDI-MS lipidomic analysis of treated samples was performed as for the 
proteomic analysis. Sections of treated and untreated skin samples were 
mounted onto the same glass slide and prepared as described in section 
5.3.2.2. Again, images were acquired sequentially in one experiment, using a 
MALDI HDMS SYNAPT G2™ system, and subsequent to analysis, were 
converted together to be visualised in one Biomap image (as seen in Figure 
5.3). Lipids that were identified in chapter 4 can be seen in both the treated and 
untreated samples. However, the expression of these lipids as shown in 
images does not appear to change significantly as a result of the skin's 
exposure to chemical irritants and sensitizers.
One m/z signal that does appear to be down-regulated in some of the human 
skin previously treated with chemical irritants and sensitizers is m/z 417. 
Although there is a matrix peak also present at 417, the high mass resolution 
achievable using the Synapt G2 ™ allows for the visualisation of the two 
separate species in Biomap images. Figure 5.3 displays an image of m/z 417 
within untreated and treated skin sections, as labelled on the image and in the 
figure legend.
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Figure 5.3: A MALDI image of a possible lipid at m/z 417. The image shows 
difference in levels of expression between: (A) human skin treated with
hydroquinone, (B) sulfamethoxazole, (C) SLS, (D) the acetone: olive oil vehicle, 
(E) DNCB, (F) cinnamaldehyde and G) human skin left, untreated.
5.4.3 Statistical Analysis
Proteomic and lipidomic spectra were taken in replicate from the epidermis. 
This was done for each of the samples that had been chemically treated, as 
well as for the vehicle and negative controls.
5.4.3.1 Statistical Analysis of Peptide Data Generated from On-  
Tissue Digests of Ex-Vivo Human Skin Treated with Irritants and 
Sensitizers
Spectra were taken in duplicate from the epidermis. This was done for each of 
the samples that had been chemically treated, as well as for the vehicle 
(Acetone: olive oil) and untreated controls. In order to obtain these spectra, 
regions of interest were drawn over the epidermis in duplicate images 
generated in Biomap (an example is given in Figure 5.4), with the resulting 
spectra being exported as text files. These spectral data were processed using 
SpecAlign™ software (Wong et al., 2005). This software was used to generate 
an average spectrum and peaks in each of the spectra were subsequently 
aligned to the position of peaks in that average spectrum. All spectra were 
normalised against the TIC.
Similarly to the statistical analyses described in Chapters 3 and 4, this was 
implemented with the objective of normalising all data sets, so that the intensity 
of signals does not appear altered in different spectra due to interfering factors, 
such as increased matrix coverage, or instrumental variation. This is important
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so that significant increases in abundance of species within a particular 
sample/spectrum may be reported with confidence. The spectral alignment is 
also critical to compensate for any mass shift between image acquisitions.
Subsequent to the normalisation processes mentioned previously, the peptide 
spectra were imported into mMass. Here, as for Chapter 3, section 3.4.2, each 
peptide mass fingerprint (PMF) was deisotoped and peak picked. With so many 
peptide and matrix signals present in the spectra, the deisotoping step was 
crucial to remove as many isotopic species as possible to reduce interference 
and the complexity of statistical plots. Peaks were picked within the m/z range 
of 920-2500 and above the signal/noise threshold of 3. Again, the m/z range 
was chosen to exclude the lipid species that have been found to be persistent 
(even subsequent to tissue washing procedures) up to approximately, m/z 910 
(the MS trace in Figure 4.2, section 4.4.1 may be used for reference).
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Figure 5.4: An example of a peptide mass fingerprint (PMF), generated from the 
epidermal region of interest within sulfamethoxazole treated human skin. The 
image to the right in ‘A’ shows the region as highlighted in pink. ‘B’, shows an 
annotated Mmass example of such a PMF.
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Principa l Com ponent Analysis (PCA)
The Principal component analysis of spectral data taken from the epidermis did 
not yield any significant correlations between the spectra and the samples they 
were generated from (i.e., no logical grouping of markers was observed). This 
is true of the PCA results generated in MarkerView (ABSciex, Cheshire, UK), 
given in Figure 5.6, and in MatLab (The MathWorks, Inc., 24 Prime Par Way, 
Natick, MA, USA), given in Figure 5.5. When reviewing the MatLab score plot, 
the replicate spectra do not seem to be grouping according to their chemical 
treatments. The score plot appears to indicate that the spectra acquired from 
the sulfamethoxazole treated samples are most similar to the vehicle control 
spectra. This is not consistent with the results seen in imaging experiments, 
such as those displayed in Figure 5.2, or with the PCA-DA results reported in 
Chapter 2, Section 2.4.2. It is thought that these PCA results have been made 
unreliable due to interfering factors, such as instrument variability, as discussed 
in section 5.5.3.
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Figure 5.5: PCA generated in MatLab; of peptide mass spectra, acquired from 
untreated human skin. The score plot shows the grouping of the spectra via 
commonalities in m/z ratios of peaks, red markers represent spectra taken from 
the dermal region; green, from the epidermal region; and blue, from areas 
thought to be fat cells. The loading plot shows the distribution of peaks and the 
frequency with which they are present in spectra.
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2
Principal Component Analysis- Discriminant Analysis (PCA-DA)
PCA-DA results for the peptide spectra are also inconclusive. The m/z peaks 
previously seen, in images, to be up-regulated in tissue treated with strong 
sensitizers, do not feature as outlying markers. This may be due to the 
presence of the protein, at some level, in all of the samples. Therefore they 
would lie closer to the centre of the loading plot. The differently treated samples 
do not group according to whether they were treated with sensitizing or irritant 
chemicals, or left untreated. Suggestions on ways to improve these statistical 
analyses can be found in the discussion section 5.5.3.
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5.4.3.1 Statistical Analysis of Lipid Data Generated from Ex-Vivo 
Human Skin Treated with Irritants and Sensitizers
Spectra were taken in replicate from the epidermis. This was done for each of 
the samples that had been chemically treated, as well as for the vehicle 
(acetone: olive oil) and untreated controls. This was done for 3 repeats of 
untreated human skin. In order to obtain these spectra, regions of interest were 
drawn in triplicate within the epidermis of each triplicate image, generated in 
Biomap (an example of which can be seen in Figure 5.8), with the resulting 
spectra being exported as text files. These spectral data were processed using 
SpecAlign™ software (Wong et a/., 2005). This software was used to generate 
an average spectrum and peaks in each of the spectra were subsequently 
aligned to the position of peaks in that average spectrum. All spectra were also 
normalised against the TIC.
Principal Component Analysis (PCA)
As with PCA results in the previous chapters, it is clear that the effects of the 
variable factors between acquisitions have once again overwhelmed any 
possible significant differences between the sample types. This is seen in the 
results generated in both the MarkerView (Figure 5.9), and MatLab (Figure 
5.10), statistical packages, where samples appear to group according to the 
date of acquisition.
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Figure 5.8: An example of 3 Lipid MS (shown overlaid in black, red and blue), 
generated from 3 different regions within the epidermis of sulfamethoxazole 
treated human skin. The image to the right, in ‘A’ shows each of the regions, 
highlighted with the brighter area of the image showing the general area of the 
epidermis. ‘B’, shows a mMass, annotated spectrum of the lipid MS overlay.
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Principal Component Analysis- Discriminant Analysis (PCA-DA)
The PCA-DA results from multiple experiments (Figure 5.11), do not group 
according to the date of acquisition as observed in the PCA. However, although 
there is some grouping of the different sample types, the score plot does not 
show a good enough degree of separation between untreated, sensitized and 
irritated tissue, in order to draw any significant conclusions.
For comparative purposes, spectra generated from a single run of direct tissue 
profiles from all of the samples was analysed using PCA-DA. The results 
observed in Figure 5.12 show grouping within each of the differently treated 
samples. There is also some evidence of similarity between the 
sulfamethoxazole and DNCB treated samples. This may be due to outlying 
species, such as m/z 577 (as seen in the loading plot). It also shows the control 
samples to be most different (grouped furthest away) from the tissues treated 
with sensitizing chemicals.
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5.5 Discussion
5.5.1 Tryptic Peptide Imaging
The up-regulation of m/z species 1183.5, and 1369.7, in skin treated with DNCB 
and sulfamethoxazole, as shown in Figure 5.2, may be significant. Through 
investigation into their identity, using RMM alone, it is feasible to attribute these 
signals to peptides belonging to interleukin 18 (IL-18). These m/z species are 
still clearly visible in all of the other samples. This would be consistent with the 
expression of IL-18 which is present in normal skin, mainly in its inactive form 
(Pro IL-18). Following the exposure of skin to a particular stimulus, the pro IL- 
18 is cleaved by caspase-1 and the active form of IL-18 secreted (Nakanishi et 
al., 2001). Therefore, it is thought that the potential IL-18 peptides (shown in 
images in Figure 5.2) in samples, untreated with sensitizers may largely belong 
to the inactive form of IL-18. IL-18 has been found to be expressed by dendritic 
cells (DC), Langerhans cells (LC) and keratinocytes (Cumberbatch et al., 2001). 
Indeed, the expression of IL-18 by keratinocytes has been found to increase as 
a result of the skin’s stimulation by chemical allergens (Kawase et al., 2003). 
This response has been observed following the exposure of murine 
keratinocytes to oxazolone and DNCB in murine (Xu et al., 1998) and human 
specimens (Naik et al., 1999).
IL-18 has been found to be of particular importance in allergic/immune 
responses as opposed to the general process of inflammation. This may mean 
that IL-18 could be a useful target for investigation when distinguishing between 
skin sensitizing chemicals and skin irritants alone. A study by Cumberbatch et
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al. (2001), suggests that the ‘availability of bio-active IL-18 is an early event 
during skin sensitization’. There is no doubt that IL-18 plays a crucial role in the 
migration of LC and accumulation of DC, during the initiation of a skin 
sensitization reaction (Cumberbatch et al., 2001). Other cytokines, such as IL- 
1(3, are found to be increased in expression after exposure to sensitizing 
compounds (Cumberbatch et al., 2001). However, IL-1(3 can also be cleaved by 
caspase-1 and in its active form is not necessarily specific to sensitization, but 
found to play a role in inflammation generally (Watanabe et al., 2007).
Signals at the m/z where any tryptic peptides of IL-1(3 might be seen, are not 
up-regulated in sensitized skin images (m/z of these peptides are given in 
Appendix IV, Table ii). This may be due to a certain degree of inflammation that 
would have occurred in all samples, during excision and treatment with the 
acetone/olive oil, vehicle and irritant chemicals. Tryptic peptides of IL-1(3 were 
not identified within human skin in this project, perhaps due to their low 
abundance. This is also the reason that is thought to explain the difficulties in 
identifying the proposed IL-18 tryptic peptides using MALDI-MS/MS. IL-18 in 
the skin is of relatively low abundance in the skin compared to serum albumin, 
collagens and keratin that have been identified in this study (Section 3.4.1). 
This means that when acquiring MS/MS of a signal that represents multiple 
species (that can be seen when using ion mobility), the product ions/amino 
acids of the peptide being looked for are masked by those belonging to more 
abundant species.
Considering currently available research into IL-18, as mentioned previously in 
this section (Cumberbatch et al., 2001, Kawase et al., 2003) it would be 
reasonable to suggest that it may be suitable as a biomarker of skin
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sensitization. In order to overcome the difficulty in identifying the IL-18 tryptic 
peptides in skin that were experienced in this study, an alternative method of 
analysis may be used to confirm the expression of IL-18 in human skin 
samples. This might be the LC-MS workflow, previously suggested in Section 
3.5.1; or the complementary use of immunohistochemistry and possibly 
polymerase chain reaction (PCR).
Another question that arises is whether or not the use of a keratinocyte, cel! 
model would be sufficient (as opposed to skin) to demonstrate induction of IL18 
in the presence of a sensitiser. The alternative to this is not yet achievable, 
since a full skin model, containing viable LC and DC, has yet to be developed 
(Aeby et al., 2010). It would be beneficial to examine the full effect of the IL-18 
response in a full skin model to investigate the effect on LCs and DCs, and 
ascertain its specificity as a sensitization biomarker. However, for a 
positive/negative test for chemical sensitizers, the cell based test alone may be 
a sufficient and cheaper route.
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5.5.2 Lipid Imaging
Many sphingomyelin species were detected, however, no change in regulation 
has been detected between treated and untreated sample images. This might 
be considered as unusual, as other studies have reported changes in regulation 
of sphingomyelin in inflamed or damaged tissue (Imokawa et al., 1999; and 
Melnik et al., 1988). It is possible that the sphingomyelin expression in all of the 
skin samples may be increased due to inflammation caused by the mechanical 
excision from the donor. Although it may be possible to get a clearer idea of 
any subtle changes in expression by using a quantitative method, such as LC- 
MS, with the use of internal lipid standards. The aforementioned may also be 
true of some ceramide species as these are also suggested to have a related 
role to sphingolipids in inflammation (Pettus etal., 2004).
Some potential change in expression can be observed in Figure 5.3, at m/z 417. 
This species can be tentatively identified as a fatty acidusing the Lipid Maps 
structural database (http://www.lipidmaps.org/data/structure. Although it is 
recognised that matrix peaks are often observed in this m/z region, the image 
observed in Figure 5.3 shows this species to be localised to a specific area 
within the tissue and so is assumed not to be associated with a matrix adduct. 
This could be expected, as other studies have shown fatty acids to play an 
active role in immune responses (Hwang, 1989).
The expression of certain fatty acids in response to irritant and sensitizing
chemicals can easily be further investigated. A lower m/z range e.g., 100-600
should be scanned for, as this would exclude many of the PC and SM species
that are routinely observed in analyses, but would include the majority of fatty
acids. Some studies have also used alternative matrices, mainly DHB (Chen et
215
al., 2008), which would be useful in ionising species that are not observed when 
using a-CHCA and also for negative mode analyses (Angel et al., 2012).
5.5.3 Statistical Analysis
Spectra were exported as regions of interest from layers of skin in images (150
x 150 pm2, spatial resolution) acquired on the MALDI-HDMS, Synapt G2
(Waters Corp., Manchester). The MarkerView PCA results in Figure 5.9 did not
yield any significant information. The markers in the scoring plot indicate that
the samples are grouping in accordance with the dates on which they were
analysed. A similar effect is observed in the MatLab PCA results (Figure 5.10).
This effect is due to the variation in signal intensity of m/z species as detected
on the different dates the analyses were performed. This means that since the
software has not been informed of the groups that are expected it has found the
variation of m/z species between different days to be as great, or more
significant than the variation between the sample types. There are a number of
explanations for this. Firstly the variation caused by instrumental factors,
changes in matrix coating, and possibly the quality of the actual skin sample
section is perhaps not fully corrected for through the application of spectral
alignment and TIC normalisation. Secondly, it is possible that this variation has
been found to be more significant due to the lack of differences in m/z signals
between sample types, caused by the low abundance of species affected by
chemical exposure. This may also explain the lack of significant results
observed in the PCA-DA of the replicate samples. The use of heat maps for the
display of statistics may help to reduce the complexity of the results, making
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them easier to interpret. This in turn may also allow for the observation of 
species of lower abundance and possible biomarkers. The issues with 
normalisation encountered here are largely to do with those surrounding the 
adequate normalisation of MALDI MSI, as discussed, in detail in Chapter 4, 
Section 4.5.2 and by Fonville et al., 2012.
In contrast, the results of the PCA-DA from the single experiment show clear 
grouping between the classes of treatments applied. As expected, the 
sensitized samples are most different to the controls, with the irritant samples 
lying mostly in the centre of the plots. Since all of the tissue samples would 
display a degree of irritation or damage, due to the excision process this result 
is expected. It is possible that by removing the inter-experimental variability, as 
indicated above, some significant pattern results have been observed.
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5.6 Conclusion
Using MALDI-MS imaging it was possible to visualise a degree of up-regulation 
of m/z species in skin sections taken from samples treated with 
sulfamethoxazole and DNCB and subsequently digested, in-situ with trypsin. 
These species have been tentatively identified as tryptic peptides of IL-18, 
however this requires confirmation via MS/MS or another, complementary 
technique, such as immunohistochemistry. Images of lipids have shown a slight 
change in expression of some m/z species, however the identity of these 
species also needs to be confirmed via MS/MS, possibly even MS3.
The statistical analysis results are promising within a single experiment. 
However, when comparing replicate data (which is undoubtedly vital), there are 
issues with normalisation across experiments and the complexity of statistical 
displays that need to be addressed.
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Chapter 6: Conclusion
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6.1 Proteomics
It was necessary to optimise skin treatments prior to characterisation and 
differential analysis of chemically exposed tissue. This was done successfully 
using intact protein analysis, PCA-DA and the MTT assay to confirm tissue 
viability. A fundamental limitation that has been discovered in intact protein 
data acquired from complex mixtures/tissue was that it is not possible to identify 
proteins based upon RMM alone. This limitation is also well documented in 
other studies, as stated in the discussion of chapter 2. In order to identify, and 
investigate proteomic species using the instrumentation available in this study, it 
was necessary to implement tryptic digestion and subsequent peptide analysis.
Initial peptide analysis was performed for the purpose of characterisation. The 
most abundant tryptic peptides found in untreated human skin belong to serum 
albumin, collagen types I, III, IV, decorin and keratin. These results are also 
substantiated by results of other investigators (Hasegawaef a/., 2007; Monroe 
etal., 2008; Moll etal., 2008; Chamcheu etal., 2011; Thrasivoulouetal., 2011).
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6.2 Lipidomics
Lipid characterisation, using a-CHCA as a matrix found the most abundant 
species in treated and untreated human skin to be phosphocholine (PC) and 
sphingomyelin (SM), in the m/z range 650-800. It is possible to image these 
species, along with LPC, PnE and others identified at low and high spatial 
resolution with little, or no analyte spreading across or off the sample. 
Theoretically it should be possible to detect other lipid species within the 
samples analysed in this study, particularly fatty acids, within the subcutaneous 
layer of skin. As such, the lipid characterisation highlighted the need for the use 
of multiple matrices with positive and negative modes of analysis.
225
6.3 Skin Responses
MALDI-MS imaging experiments have shown the ability of the technology to 
visualise changes in expression of proteomic species subsequent to varying 
chemical exposure. Some of these species have been tentatively identified as 
tryptic peptides of IL-18, however this requires confirmation via MS/MS or 
another, complementary technique, such as immunohistochemistry. Images of 
lipids have shown a slight change in expression of some m/z species, however 
the identity of these species also needs to be confirmed via MS/MS, possibly 
even MSn.
Statistical analyses show changes in detection of m/z species between sections 
of chemically treated and untreated human skin. This statement is true of the 
results within a single experiment. However, when replicate data is compared 
using unsupervised principal component analysis there are no significant results 
when using MatLab and, when using Markerview software the results show 
grouping of samples according to their day of analysis. Indicating that 
normalisation of data between different runs needs to be improved. The final 
observation relates to the complexity of the statistical plots. Statistical results 
could be more easily interpreted if they could be visualised as heat maps of the 
actual samples, as seen in the work of Fonville etal., 2012..
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6.4 Suggestions for Future Work
6.4. 1 Further Proteomic Analysis
Further investigation should be carried out to ascertain the conclusive identity of 
the species shown to be up-regulated in Figure 5.1. This may be possible via 
the LC-ESI-MS analysis of the sensitized human skin, as proposed earlier. 
However, it is also important that an alternative to mass spectrometry be used 
to validate any discovery of potential biomarkers. Immunohistochemistry (IHC) 
with the use of IL-18 specific antibodies may be used to confirm the presence of 
interleukin 18 (as suspected due to tentative identification by peptide mass of 
the up-regulated species shown in figure 5.1). IHC has been utilised previously, 
in similar studies. For example, Nipp et al., (2012) used IHC to validate the 
protein biomarkers of papillary thyroid carcinoma with lymph node metastasis 
that they had previously identified though MALDI MSI. Improvements in the 
ability of MALDI to identify peptides within tissue could be made through 
coupling it with LC (LC-MALDI). The workflow proposal here, would be to first 
dissect the different layers of skin, as much as possible (i.e. stratum 
corneum/epidermis, and subcutaneous layers) and perform a protein extraction 
procedure. This would remove any interfering species such as lipids. Next, the 
extract solution could be lyophilised to remove any volatile components 
(solvents, excess acid etc.). The lyophilised protein would be suspended in a 
more compatible solution (e.g. ammonium bicarbonate or H20  with 0.1% TFA, 
before undergoing reduction and alkylation and finally being left to digest with 
trypsin overnight.
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The resulting peptide mixture would then undergo nano-LC separation, using, 
for example, a C l 8 , reverse phase column. In order to perform this type of 
experiment it would be necessary to have the LC linked to a robot that could 
either spot fractions (at appropriate intervals), with matrix, directly onto a MALDI 
target plate, or into a microtitre well plate, to be spotted immediately subsequent 
to the completion of the run. This workflow has been employed in another study 
by Monroe et al., (2008), where LC fractionation was employed prior to MSMS, 
and alongside SIMS and MALDI imaging of the spinal cord. By employing this 
procedure it would mean that there would be a limited number of peptides within 
each fraction or well of the target plate. This would simplify the complexity of 
peptide mass fingerprints (PMFs) generated by reducing the number of 
peptides in each spot. In turn, this means that the likelihood of obtaining viable 
MS/MS of peptides to input into the MASCOT search engine, or sequence 
manually, would be increased. In addition, Monroe et al., (2008), also 
discussed the increased potential for obtaining MSMS identification of species 
that were of low abundance within the tissue being analysed, when using the 
aforementioned methodology. This would be of particular use when analysing 
skin which, as mentioned previously contains a large number of keratin and 
collagen species that may be suppressing the detection of less abundant 
species of interest.
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6.4.2 Further Lipid Analysis
Lipidomics is an area that has played a secondary role to proteomic research 
for many years. Recently, however, the biological significance of the roles of 
lipids are becoming more widely recognised. Many lipid species such as fatty 
acids and others are typically analysed in negative mode. It would therefore be 
reasonable to suggest the analysis of chemically treated and untreated skin, 
using different matrices, such as DHB and 9-aminoacridine in negative 
ionisation mode. This would provide information on different lipid groups to 
those already identified/imaged in this study. One group of molecules that may 
be of particular interest are fatty acids, known to be involved in immune 
responses.
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Appendix IV: Theoretical Digests of IL-18 and IL-113
To tentatively identify interleukin 18 peptides in images and by mass only, the 
theoretical tryptic digest was performed on the Expasy Bioinformatics resource 
portal at: http://web.expasv.org/cqi-bin/peptide mass/peptide-mass.pl. The 
digest results can be seen in table i. The peptides generated in a theoretical 
tryptic digest of IL-1 (3 were also looked for in MALDI images. The theoretical 
digest results can be seen in Table ii.
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Mass Position MC Peptide Sequence
2853.2494 141-165 1 SVPGHDNKMQFESSSYEGYF LACEK
2303.9947 149-167 1 MQFESSSYEGYFLACEKER
2018.8510 149-165 MQFESSSYEGYFLACEK
1997.8756 177-193 1 EDELGDRSIMFTVQNED
1859.9398 133-148 1 SDIIFFQRSVPGHDNK
1698.8883 81-94 1 TIFIISMYKDSQPR
1668.8778 76-89 1 DNAPRTIFIISMYK
1645.8618 116-129 1 IISFKEMNPPDNIK
1582.8509 107-120 1 ISTLSCENKIISFK
1488.7839 90-103 1 DSQPRGMAVTISVK
1401.6678 121-132 1 EMNPPDNIKDTK
1369.7110 130-140 1 DTKSDIIFFQR
1354.6341 104-115 1 CEKISTLSCENK
1265.6592 95-106 1 GMAVTISVKCEK
1183.5299 184-193 0 SIMFTVQNED
1115.6169 81-89 0 TIFIISMYK
1057.4982 121-129 0 EMNPPDNIK
1044.6411 41-49 1 LESKLSVIR
1025.5414 133-140 0 SDIIFFQR
994.4874 107-115 0 ISTLSCENK
989.6393 168-175 1 DLFKLILK
971.5196 37-44 1 YFGKLESK
961.4585 176-183 1 KEDELGDR
905.5124 95-103 0 GMAVTISVK
853.4162 141-148 0 SVPGHDNK
833.3635 177-183 0 EDELGDR
807.4359 166-171 1 ERDLFK
Table i: Theoretical tryptic digest of human IL-18, as generated at 
http://web.expasy.org/cgi-bin/peptide_mass/peptide-mass.pl.
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Mass Position #MC Peptide Sequence
2618.3745 182-204 1 NLYLSCVLKDDKPTLQLESV DPK
2087.0655 191-208 1 DDKPTLQLESVDPKNYPK
1809.9051 128-143 1 DSQQKSLVMSGPYELK
1632.7210 255-269 0 GGQDITDFTMQFVSS
1584.8115 191-204 0 DDKPTLQLESVDPK
1392.6900 121-132 1 SLNCTLRDSQQK
1365.7525 215-225 1 FVFNKIEINNK
1309.7184 180-190 1 EKNLYLSCVLK
1229.6783 117-127 1 APVRSLNCTLR
1223.6340 133-143 0 SLVMSGPYELK
1067.6823 172-181 1 IPVALGLKEK
1052.5809 182-190 0 NLYLSCVLK
810.5447 172-179 0 IPVALGLK
810.4621 214-219 1 RFVFNK
806.4189 121-127 0 _ SLNCTLR
Table ii: Theoretical tryptic digest of human IL-1 (3, as generated at 
http://web.expasy.org/cgi-bin/peptide_mass/peptide-mass.pl.
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